1. Introduction {#sec1}
===============

Viral infections continue to haunt the population dynamics ever since its discovery. The combat between the scientists and infectious diseases never seems to take a break and continue even in this contemporary world despite many advancements in the science and technology. Mathematical modeling techniques appeared as boon to the biological scientists as they provided them an artificial environment to experiment without affecting the population directly and cost effective, so they continue to attract millions of scientists even today. Modelingthe viral infections *in vivo* has caught the attention of scientists in recent years with the discoveries of many new members in the family of viral diseases like SAARS (Severe Acute Respiratory Syndrome) despite the presence of senior citizens (AIDS --- Acquired Immune Deficiency Syndrome, conjunctivitis etc.). The different approaches adopted by mathematical biologists like Huang et al. in [@b10], Herz *et.al* in [@b8] tried their hand with Delay Differential Equations and Fractional Differential Equations in [@b40] with regard to intracellular delay in viral dynamics and HIV infection Models with Non-linear incidence rates respectively while M. Pitchaimani et al. in [@b26] focussed on HIV-1 infection model with three time delays. Also, Pitchaimani and Rajaji contributed works in Stochastic Nowak - May Model analysis as in [@b27]. Also the works of R. Almeida in [@b1], Wang et al. in [@b34] is noted for its contribution to the theory in the row. In those papers, many discussions have been attempted with simulation results trying to present a clear insight in the viral dynamics. Natural query, now, in the heads are why viral dynamics deserves due attention and capitulates the interests beyond centuries. So, before getting into the model briefing, let us take a short tour on the biological aspects behind the motivation to research the viral dynamics for centuries. In general, any biologically identified organism possess immune system to safeguard itself from the enemies those attack them both anatomically and physiologically, in particular, the genus *Homo sapiens* being the largely dominating population in terms of evolution as in [@b5], [@b24] and [@b35]. The immune system of the *H. sapiens* are said to showcase two types of immune responses viz., innate and antigen mediated immunity which are further being put into broader categories of Lytic and Non-Lytic Immune responses when it comes to Antiviral immune effector mechanisms to fight against viral infections which we are about to analyze mathematically through modeling with random effects shortly. The study of viral dynamics continue to be an area of greater research interest as they give an opportunity to unearthen the mysterious behavior of the physiological mechanisms of the human body. These studies help us in deciding the factors like the type of immune response to be effected in the host system to combat the viral infection and the level of treatment such that the hosts are not being exposed to lethal complications. Also, mathematical models provide deeper insights into the various drug therapy strategies used.

Let us now shift our focus on the biological aspects of viral infections and immune responses for a short while to gain an core idea on the immunological effects on the host. As we discussed in the beginning of introduction, the Lytic and Non-Lytic immune responses play a vital role as the virus not only tend to cause infection in the susceptible cells i.e., its target victims but also tend to spend its life within the poor victims i.e., in the infected cell by replicating its viral DNA thereby adding more victims and spreading infections on a larger scale within the host system. The Lytic components kill infected cells while the Non-Lytic inhibit viral replication through soluble mediators. In the innate type of immunity response, natural killer cells can lyse infected cells and cytokines (for example, interferon $\alpha$ ((IFN-$\alpha_{1}$) and (IFN-$\beta_{1}$)) secreted by various cell types, can inhibit viral replication in a Non-Lytic fashion. In antigen mediated immune response, cytotoxic $T$ Lymphocytes (CTLs) kill infected cells, whereas antibodies neutralize free virus particles. Also, in addition, CD4${}_{+}$ and CD8${}_{+}$ $T$ cells can secrete cytokines that inhibit viral replication (e.g., IFN-$\gamma_{1}$ and tumor necrosis factor $\alpha_{1}$ (TNF-$\alpha_{1}$)). The antiviral immune effector mechanisms enter into action field, thereby discovering chances of eliminating the infectious guests (virus particles) under the capitancy of immune responses (Lytic & Non-Lytic immune responses). The relative roles of the immune responses are decided by the cytopathicity of the virus relative to its replication because if the viral cytopathicity is low in comparison with its rate of replication then a treatment that together induce both the type of immune responses are needed for action while on the contrary situation both types are given space for independent actions to get the situation (infection) under control. A study on mortality deceleration rate has been carried out by Pitchaimani and T. Eakin in [@b25].

Having had a small briefing on the viral infections and their dynamical behaviors, we now get into the mathematical analysis without any further due. However, necessary biological interpretations will be given then and there. To bring out an understanding on the significant role of mathematical modelingin viral dynamical studies, we begin with a simple mathematical model *in vivo* as given below $$\begin{aligned}
{\frac{dx}{dt} = \overset{˙}{x}} & {= \lambda - \mu x - \beta xz} \\
{\frac{dy}{dt} = \overset{˙}{y}} & {= \beta xz - ay} \\
{\frac{dz}{dt} = \overset{˙}{z}} & {= p_{1}y - c_{1}z} \\
\end{aligned}$$Here, $x$, $y$ and $z$ represent the populations of the uninfected target cells, infected target cells, and free virus particles, respectively. The uninfected cells are generated from sources within the body at rate $\lambda$ and become infected at rate $\beta xz$, where $\beta$ is the infection rate constant. The uninfected and infected cells die with rate constants $\mu$ and $a$, respectively. The virus particles are produced by the infected cells with rate constant $p_{1}$, and are removed from the system with rate constant $c_{1}$.

It is clear from the above representation that unlike other epidemic compartment models, virus models focus on the disease dynamics within an infected individual.

Let us begin our main course of action by analyzing the literature survey on the modeling of viral dynamics that suggested an effective and detailed study in this regard which has been by Bartholdy et al. ([@b4]) and Wodarz et al. ([@b36]) describing the basic dynamics of the interaction between susceptible host cells, a virus population, and immune responses that investigated the role of direct Lytic and Non-Lytic inhibition of viral replication by immune cells in viral infections, with non-linear incidence rate $\frac{\beta\alpha\lambda}{1 + q\kappa}$ and is given by the following ordinary differential equations, $$\frac{d\alpha}{dt} = \overset{˙}{\alpha} = \gamma - \mu\alpha - \frac{\beta\alpha\lambda}{1 + q\kappa}$$$$\frac{d\lambda}{dt} = \overset{˙}{\lambda} = \frac{\beta\alpha\lambda}{1 + q\kappa} - a\lambda - p\lambda\kappa$$$$\frac{d\kappa}{dt} = \overset{˙}{\kappa} = c\lambda - b\kappa,$$ $\alpha\left( 0 \right) = \alpha_{0} > 0,\qquad\lambda\left( 0 \right) = \lambda_{0} > 0,\qquad\kappa\left( 0 \right) = \kappa_{0} > 0,$.

The Pictorial illustration of the Viral Infection Model is given in the [Fig. 1](#fig1){ref-type="fig"}.

The parameters used in the system modeling with their meaning is listed in the [Table 1](#tbl1){ref-type="table"} below.Fig. 1Viral Infection Model.

We assume that the immune responses get stronger at a rate proportional to the number of infected cells, $c\lambda,$ and also decay at a rate proportional to its current strength, $b\kappa,$ here the variable $\kappa$ represents the total immunity that can be generated in response to viral infection. The parameter $p$ expresses the strength of the Lytic component, while the efficacy of the Non-Lytic component is being expressed by the parameter $q.$ The dynamics of the free virus has not been included explicitly in the model [(1)](#fd1){ref-type="disp-formula"} because ([@b4], [@b36]) assume that the free virus turnover is much faster than that of infected cells, which allows to make a quasi steady-state assumption, where the amount of free virus is proportional to the number of infected cells. Hence, the number of infected cells $\lambda$ can also be considered as a measure of virus load. In the model by  [@b4] and  [@b36], the non-linear incidence rate needs a mention with its effects in biological sense because viral infection models with other incidence rates like saturated incidence rate, linear infection rates do exist and been analyzed by many biologists, so naturally there arises a doubt in the minds how they differ from one another and their effective contribution in the analyzation process. The non-linear incidence rates brings to light that the spread of infection may be through physical movement or any other means of dispersion that an infected individual will have contact with a given number of susceptible individuals in the population. The potential to effectively disperse the disease (virus) could be thought of as being proportional to that number of susceptibles with whom the infected individual makes contact: indeed, more the contact, the infected individual has with susceptibles, the more likely the host is to effectively transmit the disease. It then follows that the magnitude of the realized disease spread could be measured, for example, in terms of the contagious spreading ability of the infected individual. Accordingly, every infected individual will be expected to realize a certain virus (or micro-parasite) spread potential. It can be noted here, that often, a non-linear function could be a better choice to account for factors such as crowding of infected individuals, multiple pathways to infection, stage of infection and its severity or protective measures taken by susceptible individuals.Table 1Parameters and Meaning --- Viral Infection Model.ParametersMeaning$\alpha$Susceptible cells$\lambda$Infected Cells$\kappa$Immune Response$\gamma$Production rate of Susceptible Cells$\mu\alpha$Natural death rate of Susceptible Cells$\beta\alpha\lambda$Infection rate in absence of Immune response$1 + q\kappa$Inhibition rate of Viral replication (Non-Lytic activity)$a\lambda$Natural death rate of Infected Cells$p\lambda\kappa$Death rate due to Immune Response$c\lambda$Production rate of Immune Cells proportional to $\lambda$$b\kappa$Decay rate of Immune Cells$p$Efficacy of the Lytic component$q$Efficacy of the Non-Lytic component

Now, let us move into the discussion of our model of interest (i.e.), a model with random effects.

2. Modeling viral dynamics {#sec2}
==========================

In the real world, all infections are subject to randomness in terms of natural transmission. The random fluctuations exhibited by the birth and death rates, transmission coefficients and the other parameters in the system to a greater or lesser extent due to environmental fluctuations was revealed by May in [@b23] while the presence of even a small amount of white noise can suppress a potential population was studied by Mao et al. ([@b22]). This implies the significance of investigating the effect of random fluctuations in the environment on population dynamics. Many authors ([@b16], [@b17], [@b29], [@b30], [@b38]) have studied the effect of environmental noise on the transmission dynamics of disease by proposing SDE models with stochastic disturbances through the perturbation technique which is a standard technique adopted by majority of the researchers in the recent years. A detailed study on the stability analysis for various mathematical models and its applicability in stochastic modeling can be grasped via ([@b3], [@b7], [@b12], [@b18], [@b19], [@b28], [@b31], [@b32], [@b41]). In our proposed study, we felt that it is wise to include the randomness by perturbing the infection rate $\frac{\beta\alpha\lambda}{1 + q\kappa}$ with white noise because the effective treatment to curb the infection spread and a detailed analysis on the dynamics of the virus in the host system can be explored thereby adding little more knowledge to the literature and the pathologists. With this measure of random effects within the host cell, studies reveal the type of immune cells to be activated in the immune system, for instance antibodies like cytotoxic lymphocytes or CD4${}_{+}$ cells in evoking a specific type of immune response in the host at the present stage of infection so that the spread may be put under the control of therapeutic mechanisms. Also, one cannot deny the fact that some evidences ([@b9], [@b13], [@b14], [@b15], [@b20], [@b37]) do exist showing that bilinear incidence rate is not much effective as non-linear incidence rate, in case, if the uninfected cells are at large. The random effect included in the infection rate can come out with additional information for curtailing the infectious period (i.e.), the chances of reducing the guest stay (virus stay) duration in the host will reduce the treatment period consequently. In short, the chemotherapy or any other means by which the host can be treated for infection will be shortened once if the dynamical behavior spread can be clearly analyzed and treated earlier. This view convinces us the introduction of randomness in the infection rate $\frac{\beta\alpha\lambda}{1 + q\kappa}$ with Gaussian White noise that takes the new form $\frac{\left( \beta + F\left( \alpha,\lambda,\kappa \right) \right)\alpha\lambda}{1 + q\kappa}\frac{dW}{dt},$ where $F\left( \alpha,\lambda,\kappa \right)$ is a locally Lipschitz-continuous function on $\mathbb{D}$ and $W$ is *i.i.d.* via perturbation techniques. In this form, let us not forget the fact that the unboundedness of contact rate have also been prevented.

In this paper, we, hereby, present the stochastic version of the deterministic system [(1)](#fd1){ref-type="disp-formula"} by defining Wiener processes on a filtered complete probability space, unless otherwise specified, $\left( \Omega,\mathcal{F},\left\{ \mathcal{F}_{t} \right\}_{t \geq 0},\mathbb{P} \right),$ where the filtration $\left\{ \mathcal{F}_{t} \right\}$ satisfies the usual conditions of right continuity, increasing while $\mathcal{F}_{0}$ contains all the $P$-null sets together with the domain $$\mathbb{D} = \left\{ \left( \alpha,\lambda,\kappa \right) \in \mathbb{R}_{+}^{3},t \geq t_{0}:\alpha > 0,\lambda > 0,\kappa > 0, \right.\left. \alpha + \lambda \leq \frac{\gamma}{\mu},\kappa \leq \frac{\gamma}{\mu}\frac{c}{b} \right\}$$ in which we analyze the stability of the equilibrium solutions of our stochastic model presented to you in the form below $$\frac{d\alpha}{dt} = \overset{˙}{\alpha} = \gamma - \mu\alpha - \frac{\beta\alpha\lambda}{1 + q\kappa} - \frac{F\left( \alpha,\lambda,\kappa \right)\alpha\lambda}{1 + q\kappa}dW$$$$\frac{d\lambda}{dt} = \overset{˙}{\lambda} = \frac{\beta\alpha\lambda}{1 + q\kappa} - a\lambda - p\lambda\kappa + \frac{F\left( \alpha,\lambda,\kappa \right)\alpha\lambda}{1 + q\kappa}dW$$$$\frac{d\kappa}{dt} = \overset{˙}{\kappa} = c\lambda - b\kappa,$$ with the initial conditions $$\alpha\left( 0 \right) = \alpha_{0} > 0,\qquad\lambda\left( 0 \right) = \lambda_{0} > 0,\qquad\kappa\left( 0 \right) = \kappa_{0} > 0,$$

The organizational structure of our paper follows the following pattern: The dynamics of the viral infection have been analyzed in this paper with the commencement of few introductory remarks on viral diseases and a bite of literature survey in this regard in introduction followed by the modeling process which displays a clear view on the care taken in modeling the viral infection without affecting the real world scenario in the maximum possible way. With this, the focus shift landed towards the methods of mathematical analyzation in a step by step process followed by observations on the conditions that would effect the disease free dynamics together with the chances of existence for chronic infection in the model. Then comes the question about the behavior on the endemic equilibrium solutions (permanency) of the infection model in the longer run and is been answered therein (i.e.), despite the treatment given to the host the chances of permanency is established via mathematical terminologies. Although, the theoretical results assure the authenticity on the dynamics, we tried to prove that these observational results hold on for a larger scale population through the theory of stationary distribution and positive recurrence exhibited by the model. Our primary objective in this paper (i.e.), observational study with empirical data is met by showcasing the simulation results in the form of graphs. An application of this observational study has been tested with a HIV infection model with Non-linear incidence rate in the follow up before concluding the paper with discussions. Some of the mathematical preliminaries that helped to bring out the observational study in this topic viz definitions, results are included in the appendix as they should not form an obstacle in the flow of our objective to analyze the effects of randomness.

Considering the biological aspects, it is crucial to have a check note on the stochastically perturbed parameter that may bloom with the possibilities of showing effective change in the host system infected with virus. In other words, the compatibility of model [(2)](#fd2){ref-type="disp-formula"} after perturbation has to be examined (i.e.), we have to look for some effective changes in the behavior of host system [(2)](#fd2){ref-type="disp-formula"} post the introduction of natural disturbances in the form randomness which would either induce or inhibit the infection.

2.1. Model analysis {#sec2.1}
-------------------

The initial step towards the existence of unique solution begins with the construction of suitable domain which meaningful in view of both aspects viz mathematical and biological. Considering the domain $\mathbb{D}$ where it is found that the coefficients of the system [(2)](#fd2){ref-type="disp-formula"} are locally Lipschitz continuous satisfying linear growth condition for any initial value $\left( \alpha_{0},\lambda_{0},\kappa_{0} \in \mathbb{D} \right)$. Thus, it is trivial that there exists unique local solution for any $t \in \left\lbrack t_{0},\tau\left( \mathbb{D} \right) \right),$ where $\tau\left( \mathbb{D} \right)$ is the random time of first exit of stochastic process (the first exit time refers to the time at which the solution moves out of the domain for the very first time once the process has begun) $\left( \alpha\left( t \right),\lambda\left( t \right),\kappa\left( t \right) \right)$ from the domain $\mathbb{D},$ started with $\left( \alpha\left( t \right),\lambda\left( t \right),\kappa\left( t \right) \right) = \left( \alpha_{0},\lambda_{0},\kappa_{0} \right) \in \mathbb{D}$ at the initial time $s \in \left\lbrack t_{0},\infty \right).$ To make the solution valid on the entire domain $\mathbb{D}$, we have to prove $$\mathbb{P}\left( \tau\left( \mathbb{D} \right) = \infty \right) = 1\quad a.s.$$For this we make another construction $$\begin{aligned}
{\mathbb{D}_{n} ≔ \left\{ \left( \alpha,\lambda,\kappa \right): \right.} & {e^{- n} < \alpha < \frac{\gamma}{\mu} - e^{- n},e^{- n} < \lambda < \frac{\gamma}{\mu} - e^{- n},} \\
 & {\left. e^{- n} < \kappa < \frac{\gamma}{\mu} - e^{- n},\alpha + \lambda \leq \frac{\gamma}{\mu},\kappa \leq \frac{\gamma}{\mu}\frac{c}{b} \right\}.} \\
\end{aligned}$$for $n \in \mathbb{N}.$ Clearly, the system [(2)](#fd2){ref-type="disp-formula"}, has a unique solution up to stopping time $\tau\left( \mathbb{D}_{n} \right).$ As our aim is clear in proving $\mathbb{P}\left( \tau\left( \mathbb{D} \right) = \infty \right) = 1$ a.s., it is enough if we could establish $\mathbb{P}\left( \tau\left( \mathbb{D} \right) < t \right) = \mathbb{P}\left( \tau\left( \mathbb{D}_{n} \right) < t \right) = 0,$ for $\left( \alpha_{0},\lambda_{0},\kappa_{0} \right) \in \mathbb{D}$ and $t \geq t_{0}.$ A detailed proof has been given following the ideas of [@b32] and the theorem on invariance of $\mathbb{D}$ due to Khasminskii in 1980 as appears in the book of [@b7] in page:132. Now, we can establish that the following theorem that will sum up the expected result for existence.

Theorem 1*Let* $\left( \alpha\left( t_{0} \right),\lambda\left( t_{0} \right),\kappa\left( t_{0} \right) \right) = \left( \alpha_{0},\lambda_{0},\kappa_{0} \right) \in \mathbb{D}$ *, where* $\mathbb{D} = \left\{ {\left( \alpha,\lambda,\kappa \right) \in \mathbb{R}_{+}^{3},t \geq t_{0}:\alpha > 0,\lambda > 0,\kappa > 0,\alpha + \lambda \leq \frac{\gamma}{\mu},\kappa \leq \frac{\gamma}{\mu}\frac{c}{b}} \right\},$ *and* $\left( \alpha_{0},\lambda_{0},\kappa_{0} \right)$ *is independent of* $W\left( t \right).$ *Then the stochastic model* [(2)](#fd2){ref-type="disp-formula"} *admits a unique continuous time, Markovian global solution* $\left( \alpha\left( t \right),\gamma\left( t \right),\kappa\left( t \right) \right)$ *on* $t \geq t_{0}$ *and this solution is invariant (a.s) with respect to* $\mathbb{D}.$

ProofLet us begin the proof with the Lyapunov function as follows $$\begin{aligned}
{V\left( \alpha,\lambda,\kappa \right) =} & {\lambda - \ln\lambda + \alpha - \ln\alpha + \left( {\frac{\gamma}{\mu} - \alpha} \right)} \\
 & {- \ln\left( {\frac{\gamma}{\mu} - \alpha} \right) + \left( {\frac{\gamma}{\mu} - \kappa} \right) - \ln\left( {\frac{\gamma}{\mu} - \kappa} \right),} \\
\end{aligned}$$defined on $\mathbb{D}$ and assume that $\mathbb{E}\left( V\left( \alpha,\lambda,\kappa \right) \right) < \infty.$Also, we get to know $V\left( \alpha,\lambda,\kappa \right) \geq 4$, for $\left( \alpha,\lambda,\kappa \right) \in \mathbb{D}.$Let $W\left( \alpha,\lambda,\kappa,t \right) = e^{- h{(t - s)}}V\left( \alpha,\lambda,\kappa \right),$ be defined on $\mathbb{D} \times \left\lbrack s,\infty \right),$ where $$\begin{aligned}
{h =} & {\frac{1}{4}\left( {2\mu + \beta\lambda\left( 1 + \alpha \right) + \frac{c\lambda}{\left( {\frac{\gamma}{\mu} - \kappa} \right)} + a + \kappa\left( p + b \right)} \right)} \\
 & {+ \sup\limits_{{(\alpha,\lambda,\kappa)} \in \mathbb{D}}\frac{1}{4}\left\{ {\frac{3\gamma^{2}}{2\mu^{2}}F^{2}\left( \alpha,\lambda,\kappa \right)} \right\}.} \\
\end{aligned}$$From Itô's Formula, upon applying the infinitesimal operator $\mathcal{L}$ on [(4)](#fd4){ref-type="disp-formula"}, we get $$\begin{aligned}
 & {\mathcal{L}V\left( \alpha,\lambda,\kappa \right) = \left( {\gamma - \mu\alpha - \frac{\beta\alpha\gamma}{1 + q\kappa}} \right)\left( {\frac{1}{\left( {\frac{\gamma}{\mu} - \alpha} \right)} - \frac{1}{\alpha}} \right)} \\
 & {+ \left( {\frac{\beta\alpha\lambda}{1 + q\kappa} - a\lambda - p\lambda\kappa} \right)\left( {1 - \frac{1}{\lambda}} \right)} \\
\end{aligned}$$ $$\begin{aligned}
 & {+ \left( c\lambda - b\kappa \right)\left( {\frac{1}{\left( {\frac{\gamma}{\mu} - k} \right)} - 1} \right)} \\
 & {+ \frac{1}{2}\frac{F^{2}\left( \alpha,\lambda,\kappa \right)\alpha^{2}\lambda^{2}}{\left( 1 + q\kappa \right)^{2}}\left( {\frac{1}{\left( {\frac{\gamma}{\mu} - \alpha} \right)^{2}} + \frac{1}{\alpha^{2}} + \frac{1}{\lambda^{2}}} \right),} \\
 & {\leq 2\mu + \beta\lambda\left( 1 + \alpha \right) + \frac{c\lambda}{\left( {\frac{\gamma}{\mu} - \kappa} \right)} + a + \kappa\left( p + b \right)} \\
 & {+ \sup\limits_{{(\alpha,\lambda,\kappa)} \in \mathbb{D}}\left\{ {\frac{3\gamma^{2}}{2\mu^{2}}\frac{F^{2}\left( \alpha,\lambda,\kappa \right)\alpha^{2}\lambda^{2}}{\left( 1 + q\kappa \right)^{2}}} \right\},} \\
 & {= 4h,} \\
\end{aligned}$$where $$\begin{aligned}
{h =} & {\frac{1}{4}\left( {2\mu + \beta\lambda\left( 1 + \alpha \right) + \frac{c\lambda}{\left( {\frac{\gamma}{\mu} - k} \right)} + a + \kappa\left( p + b \right)} \right)} \\
 & {+ \sup\limits_{{(\alpha,\lambda,\kappa)} \in \mathbb{D}}\frac{1}{4}\left\{ {\frac{3\gamma^{2}}{2\mu^{2}}F^{2}\left( \alpha,\lambda,\kappa \right)} \right\}.} \\
\end{aligned}$$So, $\mathcal{L}V\left( \alpha,\lambda,\kappa \right) \leq hV\left( \alpha,\lambda,\kappa \right),$ since $V\left( \alpha,\lambda,\kappa \right) \geq 4,$ for $\left( \alpha,\lambda,\kappa \right) \in \mathbb{D}.$Hence, we get $\mathcal{L}W\left( \alpha,\lambda,\kappa,t \right) = e^{- h{(t - s)}}\left( - hV\left( \alpha,\lambda,\kappa \right) + \mathcal{L}V\left( \alpha,\lambda,\kappa \right) \right) \leq 0.$Also, here,$\inf_{{(\alpha,\lambda,\kappa)} \in \mathbb{D} \smallsetminus \mathbb{D}_{n}}V\left( \alpha,\lambda,\kappa \right) > n + 2,$ for $n \in \mathbb{N}.$Now define $\tau_{n} ≔ \min\left\{ t,\tau\left( \mathbb{D}_{n} \right) \right\}$ and apply Dynkin's formula to get $$\begin{aligned}
 & {\mathbb{E}\left\lbrack W\left( \alpha\left( \tau_{n} \right),\lambda\left( \tau_{n} \right),\kappa\left( \tau_{n} \right),\tau_{n} \right) \right\rbrack} \\
 & {= \mathbb{E}\left\lbrack W\left( \alpha\left( s \right),\lambda\left( s \right),\kappa\left( s \right),s \right) \right\rbrack} \\
 & {+ \mathbb{E}\left\lbrack {\int_{s}^{\tau_{n}}\mathcal{L}W\left( \alpha\left( u \right),\lambda\left( u \right),\kappa\left( u \right),u \right)du} \right\rbrack} \\
 & {\leq \mathbb{E}\left\lbrack W\left( \alpha\left( s \right),\lambda\left( s \right),\kappa\left( s \right),s \right) \right\rbrack} \\
 & {= \mathbb{E}\left\lbrack V\left( \alpha\left( s \right),\lambda\left( s \right),\kappa\left( s \right) \right) \right\rbrack} \\
 & {= \mathbb{E}\left\lbrack V\left( \alpha_{0},\lambda_{0},\kappa_{0} \right) \right\rbrack} \\
\end{aligned}$$Next, to show that $\mathbb{P}\left( \tau\left( \mathbb{D}_{n} \right) < t \right) = 0,$ we take the expected value of $e^{h{(t - \tau_{n})}}V\left( \alpha\left( \tau_{n} \right),\lambda\left( \tau_{n} \right),\kappa\left( \tau_{n} \right) \right)$, (i.e.), $$\begin{aligned}
 & {\mathbb{E}\left\lbrack e^{h{(t - \tau_{n})}}V\left( \alpha\left( \tau_{n} \right),\lambda\left( \tau_{n} \right),\kappa\left( \tau_{n} \right) \right) \right\rbrack} \\
 & {= \mathbb{E}\left\lbrack e^{h{(t - s)}}e^{- h{(\tau_{n} - s)}}V\left( \alpha\left( \tau_{n} \right),\lambda\left( \tau_{n} \right),\kappa\left( \tau_{n} \right) \right) \right\rbrack,} \\
 & {= \mathbb{E}\left\lbrack e^{h{(t - s)}}W\left( \alpha\left( \tau_{n} \right),\lambda\left( \tau_{n} \right),\kappa\left( \tau_{n} \right),\tau_{n} \right) \right\rbrack,} \\
 & {\leq e^{h{(t - s)}}\mathbb{E}\left\lbrack V\left( \alpha_{0},\lambda_{0},\kappa_{0} \right) \right\rbrack,} \\
\end{aligned}$$and obtain $$\begin{aligned}
{\qquad 0} & {\leq \mathbb{P}\left( \tau\left( \mathbb{D} \right) < t \right) \leq \mathbb{P}\left( \tau\left( \mathbb{D}_{n} \right) < t \right),\qquad\text{since}\quad\mathbb{D}_{n} \subseteq \mathbb{D}} \\
 & {= \mathbb{P}\left( \tau_{n} < t \right)} \\
 & {= \mathbb{E}\left( \mathbf{1}_{\tau_{n} < t} \right),\text{where~}\mathbf{1}\text{~is~the~indicator~function}} \\
 & {\leq \mathbb{E}\left( {e^{h{(t - \tau_{n})}}\frac{V\left( \alpha\left( \tau\left( \mathbb{D}_{n} \right) \right),\lambda\left( \tau\left( \mathbb{D}_{n} \right) \right),\kappa\left( \tau\left( \mathbb{D}_{n} \right) \right) \right)}{\inf\limits_{{(\alpha,\lambda,\kappa)} \in \mathbb{D} \smallsetminus \mathbb{D}_{n}}V\left( \alpha,\lambda,\kappa \right)}\mathbf{1}_{\tau_{n} < t}} \right)} \\
 & {\leq e^{h{(t - s)}}\frac{\mathbb{E}\left( V\left( \alpha_{0},\lambda_{0},\kappa_{0} \right) \right)}{\inf\limits_{{(\alpha,\lambda,\kappa)} \in \mathbb{D} \smallsetminus \mathbb{D}_{n}}V\left( \alpha,\lambda,\kappa \right)}} \\
 & {\leq e^{h{(t - s)}}\frac{\mathbb{E}\left( V\left( \alpha_{0},\lambda_{0},\kappa_{0} \right) \right)}{n + 2}.} \\
\end{aligned}$$Since $\left. e^{h{(t - s)}}\frac{\mathbb{E}\left( V\left( \alpha_{0},\lambda_{0},\kappa_{0} \right) \right)}{n + 2}\rightarrow 0 \right.$ as $\left. n\rightarrow\infty \right.$ for all $\left( \alpha_{0},\lambda_{0},\kappa_{0} \right) \in \mathbb{D}_{n}$ (for large $n$), and for all fixed $t \in \left\lbrack s,\infty \right).$Thus, $\mathbb{P}\left( \tau\left( \mathbb{D} \right) < t \right) = \mathbb{P}\left( \tau\left( \mathbb{D}_{n} \right) < t \right) = 0,$ for $\left( \alpha_{0},\lambda_{0},\kappa_{0} \right) \in \mathbb{D}$ and $t \geq t_{0},$ that is, $\mathbb{P}\left( \tau\left( \mathbb{D} \right) = \infty \right) = 1.$This proves the invariance property and the global existence of the solution $\left( \alpha\left( t \right),\lambda\left( t \right),\kappa\left( t \right) \right)$ on $\mathbb{D}$ whereas the continuity and uniqueness of the solution is given by the theorem in [Appendix](#app){ref-type="sec"}.  □

Thus, the above theorem assures that the system does not show up any adverse effects on the host even after including randomness in the infective rate of the virus and guarantee positive immune response.

Also, we can conclude that our model [(2)](#fd2){ref-type="disp-formula"} has shown good compatibility in finding unique global solution which would enhance the study of global dynamics of the viral infection with respect to Lytic and Non-Lytic immune responses in an effective way.

Once the existence is confirmed, the next move is to analyze the nature and number of solutions that the system [(2)](#fd2){ref-type="disp-formula"} would admit in the dynamics of viral infection will be of more concern. It is clear that the stochastic model in our consideration admits atmost two equilibrium solutions, namely, infection-free equilibrium and endemic equilibrium.

We are familiar with certain viral infections which have signs of curing the disease to a little extent when the immune responses from the innate and adaptive immunity are stronger enough to eradicate the entire infection in the host system. In such cases, the mathematical models admit infection-free equilibrium which will be undertaken into analytic study in the following section. We are pretty aware of the fact that the Lytic immune responses have the ability to kill the infected cells henceforth bringing down the population of infected cells to a larger extent and also preventing the replication of virus inside the host to a minimal level which can be accelerated high with Non-Lytic immune response. In order to make a decision on the type of immune response to be effected in the infected individual to become infection-free it is pivotal to analyze the stability of our proposed model [(2)](#fd2){ref-type="disp-formula"} with respect to this condition of equilibrium to initiate Lytic immune response based on the nature of infection caused.

2.2. Stability around disease free dynamics {#sec2.2}
-------------------------------------------

We begin our discussion on the stochastic asymptotic stability of infection-free equilibrium solution of system [(2)](#fd2){ref-type="disp-formula"} with reference to the existing mathematical theories via Lyapunov technique.

The infection-free equilibrium solution $\left( \alpha_{1},\lambda_{1},\kappa_{1} \right)$ is obtained when $$\alpha_{1} = \frac{\gamma}{\mu},\qquad\lambda_{1} = 0,\qquad\kappa_{1} = 0$$We first identify the conditions that has to be met by the system [(2)](#fd2){ref-type="disp-formula"} to exhibit asymptotic stability of infection-free equilibrium solution via the following theorem. (i.e.), we know that not all viral infections are chronical in the sense that there are certain viral infections namely the swine flu, chikungunya, chicken pox, smallpox etc which can be cured by proper treatment. As the model we have constructed is a generalized one for all type of viral infections, it is important to analyze the criteria in which the model [(2)](#fd2){ref-type="disp-formula"} admits disease free dynamics. The mathematical theory that aids help, is the concept of Basic Reproduction Number $R_{0}$, a quantity that tells about the secondary infection that can be caused by an single infected host during his entire infection period. To make use of this, we first construct a Lyapunov function as follows: $$V_{1}\left( \alpha,\lambda,\kappa \right) = \frac{1}{2}\left( {\alpha + \lambda - \frac{\gamma}{\mu}} \right)^{2} + K_{1}\lambda + K_{2}\kappa^{2}$$where $K_{1} = \frac{\gamma}{\mu} + \frac{\gamma}{a}$ and $K_{2} = \frac{p\gamma}{2ac}.$

The fact that if upon acting the infinitesimal generator on this Lyapunov functional, the resultant is negative definite on $\mathbb{D}$, then the system admits disease free dynamics is well known. In other words, the infection-free equilibrium solution $\left( \alpha_{1},\lambda_{1},\kappa_{1} \right)$ of [(8)](#fd8){ref-type="disp-formula"} is stochastically asymptotically stable if $R_{0} \leq 1,$ where $R_{0} = \frac{\gamma\beta}{a\mu}$ is the basic reproduction number of virus. It is evident from the following steps: $$\begin{aligned}
{\mathcal{L}V_{1}} & {= \left( {\gamma - \mu\alpha - \frac{\beta\alpha\lambda}{1 + q\kappa}} \right)\left( {\alpha + \lambda - \frac{\gamma}{\mu}} \right)} \\
 & {\mspace{2600mu} + \left( {\frac{\beta\alpha\lambda}{1 + q\kappa} - a\lambda - p\lambda\kappa} \right)\left( {\left( {\alpha + \lambda - \frac{\lambda}{\mu}} \right) + K_{1}} \right)} \\
 & {\mspace{2600mu} + \left( c\lambda - b\kappa \right)\left( 2\kappa K_{2} \right),} \\
 & {= \left( {\gamma - \mu\alpha - a\lambda - p\lambda\kappa} \right)\left( {\alpha + \lambda - \frac{\gamma}{\mu}} \right)} \\
 & {\mspace{2600mu} + K_{1}\left( {\frac{\beta\alpha\lambda}{1 + q\kappa} - a\lambda - p\lambda\kappa} \right)} \\
 & {\mspace{2600mu} + 2K_{2}k\left( c\lambda - b\kappa \right),} \\
 & {\leq - \mu\left( {\alpha - \frac{\gamma}{\mu}} \right)^{2} - a\lambda^{2} - p\alpha\lambda\kappa} \\
 & {\mspace{2600mu} - p\kappa\lambda^{2} + \alpha\lambda\left( \left( R_{0} - 1 \right)\left( a + \mu \right) \right)} \\
 & {\mspace{2600mu} - 2K_{2}b\kappa^{2}.} \\
\end{aligned}$$Thus, we sum up our examined results on disease free dynamics with the theorem below

Theorem 2*The infection-free equilibrium solution* $\left( \alpha_{1},\lambda_{1},\kappa_{1} \right)$ *of* [(2)](#fd2){ref-type="disp-formula"} *is stochastically asymptotically stable on* $\mathbb{D}$ *as* [(8)](#fd8){ref-type="disp-formula"} *becomes negative definite on* $\mathbb{D}$ *if* $R_{0} \leq 1,$ *where* $R_{0} = \frac{\gamma\beta}{a\mu}$ *is the basic reproduction number of virus.*

Thus, the stochastic system [(2)](#fd2){ref-type="disp-formula"} with perturbation in the infective rate $\frac{\beta\alpha\lambda}{1 + q\kappa}$ stabilizes on $\mathbb{D}.$ Thus, we have found sufficient condition based on which the system [(2)](#fd2){ref-type="disp-formula"} stabilizes on $\mathbb{D}$. It is clear from Eq. [(8)](#fd8){ref-type="disp-formula"}, the spread of infection in the host system is dependent on the basic reproduction number as any other deterministic system.

Thus, in general, if the infection rate can be controlled by stimulating the activities of CytoToxic Lymphocytes (CTL) and cytokines in the host immune system through chemotherapy for some viral infectious diseases as they kill infected cells whereas antibodies neutralize the free virus particles, our system [(2)](#fd2){ref-type="disp-formula"} admits the chances of disease free equilibrium even though persistence of the model [(2)](#fd2){ref-type="disp-formula"} has been discussed in later sections. Hereby, we can also arrive at the conclusion that together with Non-Lytic immune response (i.e.), increase in the activities of CD$4_{+}$ and CD8${}_{+}$ cells in the host immune system, the success rate is increased with higher probability.

Remarks 1The empirical evidence that strengthens the above arguments in [Theorem 2](#thm2){ref-type="statement"} have been presented in [Fig. 2](#fig2){ref-type="fig"} based on the simulation results obtained from the parameter values in [Table 2](#tbl2){ref-type="table"}. In addition, we also find the disease free equilibrium at the initial values $\left( \alpha_{0},\lambda_{0},\kappa_{0} \right) = \left( 100,15,45 \right)$ together with the parameter values $\gamma = 300,\mspace{1300mu}\beta = 0.002,\mspace{1300mu} a = 0.9,\mspace{1300mu}\mu = 0.8,\mspace{1300mu} p = 0.4,\mspace{1300mu} q = 0.5,\mspace{1300mu} b = 0.31,\mspace{1300mu} c = 0.95$ giving $R_{0} = 0.8333 < 1$ at $\left( \alpha_{1},\lambda_{1},\kappa_{1} \right) = \left( 375,0,0 \right)$ adding strength to the stability of infection free equilibrium empirically.

Now, we are interested in the inquiry about the endemic equilibrium solution's stability on $\mathbb{D}$ of the model [(2)](#fd2){ref-type="disp-formula"} as our main aim is to try to control the viral infection although the host continue to survive with the chronic infection till the end of life with the intention to increase the life expectancy of the host. In other words, to prolong the life period of the host infected with chronic infection. So, it would be logical to study the stability behavior of the system [(2)](#fd2){ref-type="disp-formula"} when the host lives with persistent viral infection. So, without further due we proceed towards the investigation to substantiate the conditions for permanency of infection.

2.3. Stochastic stability of endemic equilibrium {#sec2.3}
------------------------------------------------

Many viral infections are chronic in nature, so it is very crucial to make an analytical study on their permanence in the host. For instance, consider HIV infection which shows no symptoms at initial state but kills the host in matter of no time as it grows very fast without any indication of its presence in the system. In such cases, it is important to sketch out a check note that any such stage the disease has to be controlled with medications. So here, the discussion is all about the mathematical theory on stochastic stability of the endemic equilibrium solution $\left( \alpha_{2},\lambda_{2},\kappa_{2} \right)$ of the system [(2)](#fd2){ref-type="disp-formula"} given by $$\begin{aligned}
\alpha_{2} & {= \frac{\left( a + p\kappa_{2} \right)\left( 1 + q\kappa_{2} \right)}{\beta} = \frac{c\gamma\left( 1 + q\kappa_{2} \right)}{c\mu + \left( b\beta + c\mu q \right)\kappa_{2}},} \\
\lambda_{2} & {= \frac{b\kappa_{2}}{c},} \\
\kappa_{2} & {= \frac{- \left( pc\mu + ab\beta + ac\mu q \right)}{2\left( bp\beta + c\mu pq \right)}} \\
 & {+ \frac{\sqrt{\left( pc\mu + ab\beta + ac\mu q \right)^{2} - 4p\left( b\beta + c\mu q \right)\left( ac\mu - c\gamma\beta \right)}}{2\left( bp\beta + c\mu pq \right)}.} \\
\end{aligned}$$

As we have seen earlier in the previous lines, the model [(2)](#fd2){ref-type="disp-formula"} manifests disease free equilibrium if $R_{0} < 1$, so the natural flip would be unique endemic equilibrium solution if $R_{0} > 1$ and $F\left( \alpha_{2},\lambda_{2},\kappa_{2} \right) = 0$ and the stability is established by tracing the following steps that leads to theorem which would cumulate our scrutiny. With the Lyapunov functional, $$V_{2} = \frac{1}{2}\left( \alpha - \alpha_{2} \right)^{2} + n\left( {\lambda - \lambda_{2} - \lambda_{2}\ln\frac{\lambda}{\lambda_{2}}} \right) + \frac{b}{2}\left( \kappa - \kappa_{2} \right)^{2}.$$the infinitesimal generator acting on the Lyapunov function $V_{2}$ can be written as: $$\begin{aligned}
{\mathcal{L}V_{2}} & {= \left( {\gamma - \mu\alpha - \frac{\beta\alpha\lambda}{1 + q\kappa}} \right)\left( \alpha - \alpha_{2} \right)} \\
 & {\mspace{2600mu} + n\left( {\frac{\beta\alpha\lambda}{1 + q\kappa} - a\lambda - p\lambda\kappa} \right)\left( {1 - \frac{\lambda_{2}}{\lambda}} \right)} \\
 & {\mspace{2600mu} + K_{1}\left( c\lambda - b\kappa \right)\left( \kappa - \kappa_{2} \right)} \\
 & {\mspace{2600mu} + \frac{1}{2}\frac{F^{2}\left( \alpha,\lambda,\kappa \right)\alpha^{2}\lambda^{2}}{\left( 1 + q\kappa \right)^{2}}\left( {n\frac{\lambda_{2}}{\lambda^{2}}} \right),} \\
\end{aligned}$$ $$\begin{aligned}
 & {= \left( {- \mu\left( \alpha - \alpha_{2} \right) - \left( {\frac{\beta\alpha\lambda}{1 + q\kappa} - \frac{\beta\alpha\lambda}{1 + q\kappa_{2}}} \right)} \right)\left( \alpha - \alpha_{2} \right)} \\
 & {\mspace{2600mu} + n\left\lbrack {\left( {\frac{\beta\alpha}{1 + q\kappa} - \frac{\beta\alpha_{2}}{1 + q\kappa_{2}}} \right) - p\left( \kappa - \kappa_{2} \right)} \right\rbrack\left( \lambda - \lambda_{2} \right)} \\
 & {\mspace{2600mu} + K_{1}\left\lbrack c\left( \lambda - \lambda_{2} - b\left( \kappa - \kappa_{2} \right) \right) \right\rbrack + \frac{1}{2}\frac{F^{2}\left( \alpha,\lambda,\kappa \right)\alpha^{2}\lambda^{2}}{\left( 1 + q\kappa \right)^{2}}\left( {n\frac{\lambda_{2}}{\lambda^{2}}} \right),} \\
 & {= - \mu\left( \alpha - \alpha_{2} \right)^{2} - \frac{\beta\lambda}{\left( 1 + q\kappa \right)}\left( \alpha - \alpha_{2} \right)^{2}} \\
 & {\mspace{2600mu} + \left( \frac{q\beta\alpha_{2}\lambda_{2}}{\left( 1 + q\kappa \right)\left( 1 + q\kappa_{2} \right)} \right)\left( \alpha - \alpha_{2} \right)\left( \kappa - \kappa_{2} \right)} \\
 & {\mspace{2600mu} - \left\lbrack {\frac{bn^{2}}{c} + \frac{bn^{2}q\beta}{c\left( 1 + q\kappa \right)\left( 1 + q\kappa_{2} \right)}} \right\rbrack\left( \kappa - \kappa_{2} \right)^{2}} \\
 & {\mspace{2600mu} + \frac{1}{2}\frac{F^{2}\left( \alpha,\lambda,\kappa \right)\alpha^{2}\lambda^{2}}{\left( 1 + q\kappa \right)^{2}}\left( {n\frac{\lambda_{2}}{\lambda^{2}}} \right).} \\
\end{aligned}$$Let $E_{1} = \sqrt{\frac{q\beta bn^{2}}{2c}}\frac{1}{\left( 1 + q\kappa \right)\left( 1 + q\kappa_{2} \right)}\left( \kappa - \kappa_{2} \right)$ and $E_{2} = \sqrt{\frac{2cq\beta\alpha_{2}\lambda_{2}}{bn^{2}}}\left( \alpha - \alpha_{2} \right).$

Now, the above eqn takes the form as follows $$\begin{aligned}
{\mathcal{L}V_{2}} & {\leq - \left( {\mu - \frac{4cq\beta\lambda_{2}}{b\alpha_{2}}} \right)\left( \alpha - \alpha_{2} \right)^{2} - \frac{b\alpha_{2}^{2}}{c}\left( \kappa - \kappa_{2} \right)^{2}} \\
 & {\mspace{2600mu} + \frac{1}{2}\frac{F^{2}\left( \alpha,\lambda,\kappa \right)\alpha^{2}\alpha_{2}\lambda_{2}}{\left( 1 + q\kappa \right)^{2}}.} \\
\end{aligned}$$It should be noted that $\mathcal{L}V_{2}\left( \alpha,\lambda,\kappa \right) = 0$ only at $\left( \alpha_{2},\lambda_{2},\kappa_{2} \right).$ Table 2Parameters and Values --- Disease free dynamics.ParameterValueParameterValue$\gamma$180$p$0.04$\mu$0.5$q$0.005$\beta$0.001$b$0.31$a$0.8$c$0.025Table 3Parameters and Values --- Endemic infection dynamics.ParameterValueParameterValue$\gamma$180$p$0.25$\mu$0.5$q$0.68$\beta$0.7$b$0.15$a$0.25$c$0.5

By choosing suitable functions $F\left( \alpha,\lambda,\kappa \right)$, we can obtain $\mathcal{L}V\left( \alpha,\lambda,\kappa \right) < 0$ on $\mathbb{D} \smallsetminus \left( \alpha_{2},\lambda_{2},\kappa_{2} \right).$ Thus, $\mathcal{L}V_{2}\left( \alpha,\lambda,\kappa \right)$ becomes negative definite on $\mathbb{D}$ for some suitable $F\left( \alpha,\lambda,\kappa \right).$ The existence of such type of functions is apparent when we look at the system [(20)](#fd20){ref-type="disp-formula"} in the later section, with which we carried out our empirical study.

Biologically, irrespective of the adaptive and innate immune responses by the Lytic and Non-Lytic components the disease continues to exist in the host but stabilizes globally on $\mathbb{D}.$ As we said in the beginning, the summary leads to the following theorem:

Theorem 3*The endemic equilibrium solution* $\left( \alpha_{2},\lambda_{2},\kappa_{2} \right)$ *of the system* [(2)](#fd2){ref-type="disp-formula"} *is stochastically asymptotically stable on* $\mathbb{D}$ *if* $R_{0} > 1$ *;* $F\left( \alpha_{2},\lambda_{2},\kappa_{2} \right) = 0$ *and also satisfies* $\eta\left( \alpha,\lambda,\kappa \right) \leq 0,$ *where* $$\begin{aligned}
{\eta\left( \alpha,\lambda,\kappa \right)} & {= - \left( {\mu - \frac{4cq\beta\alpha_{2}\lambda_{2}}{bn^{2}}} \right)\left( \alpha - \alpha_{2} \right)^{2} - \frac{bn^{2}}{c}\left( \kappa - \kappa_{2} \right)^{2}} \\
 & {+ \frac{1}{2}\frac{F^{2}\left( \alpha,\lambda,\kappa \right)\alpha^{2}\lambda^{2}}{\left( 1 + q\kappa \right)^{2}}\left( {n\frac{\lambda_{2}}{\lambda^{2}}} \right),} \\
\end{aligned}$$ *for* $n = \alpha_{2}$ *and* $b = \frac{p\alpha_{2}}{c} + \frac{q\beta\alpha_{2}^{2}}{c\left( 1 + q\kappa_{2} \right)\left( 1 + q\kappa \right)}.$

This condition though assures the existence of disease in the host system in the long-run yet promises of the stabilizing chances of the infection in host so that the virulence of viral strains can be reduced which in turn increases the chances of survival of the host despite chronic viral infection. In such cases, our aim takes a small diversion to decide on the type of immune responses to be effected on the host through treatment and the admissible level of treatment to be given such that the host is less prone to the side effects of the treatment while enhancing the longevity.

The study in this article provides a general notion for the survival of the host with permanent infection in the long run. It may also exhibit two fates (normal or apoptosis). Since, this study is a mathematical analysis of the model, a general condition that would fit both would be more appropriate thereby strongly assuring the possibilities of survival of the host in long term so that whatever be the fate the host may experience, the physician may choose appropriate treatment accordingly.Fig. 2By taking the parameters values as in [Table 2](#tbl2){ref-type="table"}, for the initial values $\left( \alpha_{0},\lambda_{0},\kappa_{0} \right) = \left( 125,25,75 \right)$, and upon simulating the model given by Eq. [(20)](#fd20){ref-type="disp-formula"}, we get the infection-free equilibrium $\left( \alpha_{1},\lambda_{1},\kappa_{1} \right) = \left( 360,0,0 \right)$ and $R_{0} = 0.4500 < 1$, clearly, the model admits stochastically asymptotically stable solution around the disease-free equilibrium for the above parameters from which we can conclude that the disease free equilibrium agrees with [Theorem 2](#thm2){ref-type="statement"} under the assumed conditions.Fig. 3By taking the parameters values as in [Table 3](#tbl3){ref-type="table"}, for the initial values $\left( \alpha_{0},\lambda_{0},\kappa_{0} \right) = \left( 125,25,75 \right)$, and upon simulating the model given by Eq. [(20)](#fd20){ref-type="disp-formula"}, we get the endemic equilibrium $\left( \alpha_{2},\lambda_{2},\kappa_{2} \right) = \left( 226.6796,8.7951,29.3170 \right)$ and $R_{0} = 1.0080e + 03 > 1$. Clearly, the model admits stochastically asymptotically stable solution around the endemic equilibrium for the above parameters from [Table 3](#tbl3){ref-type="table"}, with which we can draw a conclusion that the endemic equilibrium agrees with [Theorem 3](#thm3){ref-type="statement"} under the assumed conditions.

Remarks 2The conditions in the above [Theorem 3](#thm3){ref-type="statement"} are lived up with the support of empirical data that has been put into simulation with values in [Table 3](#tbl3){ref-type="table"} and has been showcased by [Fig. 3](#fig3){ref-type="fig"} We emphasis that the values are mere samples and similar kind of choice for parameters that would result in $R_{0} > 1$ will always lead to endemicity. For instance, consider the parameter values $\gamma = 300,\mspace{1300mu}\beta = 0.002,\mspace{1300mu} a = 0.8,\mspace{1300mu}\mu = 0.5,\mspace{1300mu} p = 0.04,\mspace{1300mu} q = 0.005,\mspace{1300mu} b = 0.31,$ $\mspace{1300mu} c = 0.025$ resulted in endemic (permanent) infection at $\left( \alpha_{2},\lambda_{2},\kappa_{2} \right) = \left( 496.4030,53.2950,4.2980 \right)$ with $R_{0} = 1.500 > 1$ for the initial values $\left( \alpha_{0},\lambda_{0},\kappa_{0} \right) = \left( 100,15,45 \right).$

The choice of parameters above has been chosen carefully after a detailed study in the literature so that they will give a realistic empirical support to the results as the authors could not afford a biological experiment. Even then the parameters are meticulously chosen that at any point they will not breach the underlying biological phenomena.

To achieve global stability, it is important to analyze the dynamics of disease for any initial conditions and is achieved by using persistence property which implies that the disease continues to exist for any initial conditions over a larger period. Next, we move on to the persistence theory of stochastically perturbed model [(2)](#fd2){ref-type="disp-formula"} as it is a logical leap with the establishment of the conditions for the stability of endemic equilibrium solution.

2.4. Persistency --- infection in long run {#sec2.4}
------------------------------------------

Let us begin this analysis by looking at the persistence theory with the hope for some useful results. The infection over a larger period of time has been given after a detailed study on a theorem given by [@b21] in his paper. Following similar ideas of proof for our system [(2)](#fd2){ref-type="disp-formula"} we came out with the following theorem which validates our statement for the persistency.

Theorem 4*If* $s_{1} = \mu$ *and* $\Psi\left( \frac{\gamma}{\mu} \right) > 0,$ *then for any initial value* $\left( \alpha\left( 0 \right),\lambda\left( 0 \right),\kappa\left( 0 \right) \right) \in \mathbb{D},$ *the solution* $\left( \alpha\left( t \right),\lambda\left( t \right),\kappa\left( t \right) \right)$ *of system* [(2)](#fd2){ref-type="disp-formula"} *has the property that*1.$\lim_{t\rightarrow\infty}\inf\frac{1}{t}\int_{0}^{t}\alpha\left( u \right)du \geq \frac{\gamma\left( bs_{1} + \gamma qc \right)}{\left( {\mu bs_{1} + \gamma qc\mu + \beta\gamma b} \right)}\quad a.s.,$2.$\lim_{t\rightarrow\infty}\inf\frac{1}{t}\int_{0}^{t}\lambda\left( u \right)du \geq \frac{\Psi\left( \frac{\gamma}{\mu} \right)}{\left( \frac{\beta\gamma b}{\mu\left( \mu b + qc\gamma \right)} \right)\left( {\beta A_{1} - \frac{F^{2}\left( \alpha,\lambda,\kappa \right)\gamma^{2}{A_{1}}^{2}}{2\mu}} \right)}\mspace{650mu} a.s.,$ *where* $A_{1} = \frac{\mu b}{\mu b + q\gamma c}$3.$\lim_{t\rightarrow\infty}\inf\frac{1}{t}\int_{0}^{t}\kappa\left( u \right)du \geq \frac{\gamma c}{\mu b}\quad a.s.$

ProofLet $\left( \alpha\left( t \right),\lambda\left( t \right),\kappa\left( t \right) \right)$ be a solution of system [(2)](#fd2){ref-type="disp-formula"} with any initial value $\left( \alpha\left( 0 \right),\lambda\left( 0 \right),\kappa\left( 0 \right) \right) \in \mathbb{D}$.By [Theorem 1](#thm1){ref-type="statement"}, it is evident that $\lambda\left( t \right) \leq \frac{\gamma}{s_{1}}$ for all $\omega \in \Omega$.From Eq. [(1)](#fd1){ref-type="disp-formula"} of system [(2)](#fd2){ref-type="disp-formula"}, $$\begin{aligned}
{d\alpha\left( t \right)} & {\geq \left( {\gamma - \mu x - \frac{\beta\alpha\lambda}{1 + q\kappa}} \right)dt - F\left( \alpha,\lambda,\kappa \right)dWt,} \\
 & {= \left\lbrack {\gamma - \left( {\mu + \frac{\beta\alpha\frac{\gamma}{s_{1}}}{1 + q\frac{\gamma c}{s_{1}b}}} \right)\alpha} \right\rbrack dt - F\left( \alpha,\lambda,\kappa \right)dWt,} \\
 & {= \left\lbrack {\gamma - \left( {\mu + \frac{\beta}{\left( {\frac{s_{1}}{\gamma} + \frac{qc}{b}} \right)}} \right)\alpha} \right\rbrack dt - F\left( \alpha,\lambda,\kappa \right)dWt,} \\
 & {= \left\lbrack {\gamma - \left( \frac{\mu bs_{1} + \gamma qc\mu + \beta\gamma b}{bs_{1} + \gamma qc} \right)\alpha} \right\rbrack dt - F\left( \alpha,\lambda,\kappa \right)dWt.} \\
\end{aligned}$$Upon integration and dividing on both sides by $t,$ we get $$\begin{aligned}
 & {\left( \frac{\mu bs_{1} + \gamma qc\mu + \beta\gamma b}{bs_{1} + \gamma qc} \right)\frac{1}{t}\int_{0}^{t}\alpha\left( u \right)du} \\
 & {\geq \gamma - \frac{\alpha\left( t \right) - \alpha\left( 0 \right)}{t}} \\
 & {- \frac{F\left( \alpha,\lambda,\kappa \right)}{t}\int_{0}^{t}\alpha\left( u \right)\lambda\left( u \right)dW\left( u \right),} \\
\end{aligned}$$By Strong Law of Large Numbers for local martingales, We have $$\lim\limits_{t\rightarrow\infty}\left( {\frac{\alpha\left( t \right) - \alpha\left( 0 \right)}{t} - \frac{F\left( \alpha,\lambda,\kappa \right)}{t}\int_{0}^{t}\alpha\left( u \right)\lambda\left( u \right)dW\left( u \right)} \right) = 0\quad a.s.$$From Eqs. [(11)](#fd11){ref-type="disp-formula"} & [(12)](#fd12){ref-type="disp-formula"}, We obtain $$\operatorname{lim\ inf}\frac{1}{t}\int\limits_{0}^{t}\alpha\left( u \right)du \geq \frac{\gamma\left( bs_{1} + \gamma qc \right)}{\left( {\mu bs_{1} + \gamma qc\mu + \beta\gamma b} \right)}\quad a.s.$$Thus we proved the assertion [(1)](#fd1){ref-type="disp-formula"} *.*To prove [(2)](#fd2){ref-type="disp-formula"}, we perform the following steps,By the Itô's formula, the Eq. [(2)](#fd2){ref-type="disp-formula"} of the system [(2)](#fd2){ref-type="disp-formula"} takes the form as follows, $$d\log\left( \lambda\left( t \right) \right) = \left( {\frac{\beta\alpha}{1 + q\kappa} - a - p\kappa - \frac{1}{2}\frac{F^{2}\left( \alpha,\lambda,\kappa \right)}{\left( 1 + q\kappa \right)^{2}}\alpha^{2}} \right)dt + \frac{F\left( \alpha,\lambda,\kappa \right)}{1 + q\kappa}\alpha dWt.$$ Also, we know $k \leq \frac{\gamma}{\mu}\frac{c}{b},$ then $$\begin{aligned}
{d\log\left( \lambda\left( t \right) \right) \geq} & {\left( {\frac{\beta\alpha}{1 + q\frac{\gamma c}{\mu b}} - a - p\frac{\gamma}{\mu}\frac{c}{b} - \frac{1}{2}\frac{F^{2}\left( \alpha,\lambda,\kappa \right)}{\left( {1 + q\frac{\gamma c}{\mu b}} \right)^{2}}\alpha^{2}} \right)dt} \\
 & {+ \frac{F\left( \alpha,\lambda,\kappa \right)}{\left( {1 + q\frac{\gamma c}{\mu b}} \right)}\alpha dWt,} \\
{d\log\left( \lambda\left( t \right) \right) \geq} & \left( {\frac{\beta\mu b}{\mu b + q\gamma c}\alpha - \left( {a + \frac{p\gamma c}{\mu b}} \right)} \right) \\
 & {\left( {- \frac{1}{2}\frac{F^{2}\left( \alpha,\lambda,\kappa \right)\left( \mu b \right)^{2}}{\left( \mu b + q\lambda c \right)^{2}}\alpha^{2}} \right)dt} \\
 & {+ \frac{F\left( \alpha,\lambda,\kappa \right)\mu b}{\mu b + q\gamma c}\alpha dWt,} \\
 & {= \Psi\left( \alpha \right)dt + \frac{F\left( \alpha,\lambda,\kappa \right)\mu b}{\mu b + q\gamma c}\alpha dWt,} \\
\end{aligned}$$where $\Psi\left( \alpha \right) = \left( {\frac{\beta\mu b}{\mu b + q\gamma c}\alpha - \left( {a + \frac{p\gamma c}{\mu b}} \right) - \frac{1}{2}\frac{F^{2}\left( \alpha,\lambda,\kappa \right)\left( \mu b \right)^{2}}{\left( \mu b + q\gamma c \right)^{2}}\alpha^{2}} \right)$.Integrating on both sides, we get $$\log\left( \lambda\left( t \right) \right) \geq \log\left( \lambda\left( 0 \right) \right) + \int_{0}^{t}\Psi\left( \alpha\left( u \right) \right)du + \int_{0}^{t}\frac{F\left( \alpha,\lambda,\kappa \right)\mu b}{\mu b + q\gamma c}\alpha\left( u \right)dW\left( u \right)$$ Take $\frac{\mu b}{\mu b + q\gamma c} = A_{1}$, Eq. [(14)](#fd14){ref-type="disp-formula"} becomes, $$\log\left( \lambda\left( t \right) \right) \geq \log\left( \lambda\left( 0 \right) \right) + \int_{0}^{t}\Psi\left( \alpha\left( u \right) \right)du + A_{1}\int_{0}^{t}F\left( \alpha,\lambda,\kappa \right)\alpha\left( u \right)dW\left( u \right).$$ Next, we proceed in computing $$\begin{aligned}
 & {\Psi\left( \alpha \right) - \Psi\left( \frac{\gamma}{s_{1}} \right)} \\
 & {= \mspace{1300mu}\beta A_{1}\alpha - \left( {a + \frac{p\gamma c}{\mu b}} \right) - \frac{1}{2}A_{1}^{2}F\left( \alpha,\lambda,\kappa \right)^{2}\alpha^{2} - \beta A_{1}\frac{\gamma}{s_{1}}} \\
 & {+ \left( {a + \frac{p\gamma c}{\mu b}} \right) + \frac{1}{2}A_{1}^{2}F\left( \alpha,\lambda,\kappa \right)^{2}\left( \frac{\gamma}{s_{1}} \right)^{2},} \\
 & {= - \beta A_{1}\left( {\frac{\gamma}{s_{1}} - \alpha} \right) + \frac{1}{2}A_{1}^{2}F^{2}\left( \alpha,\lambda,\kappa \right)\left( {\frac{\gamma^{2}}{s_{1}^{2}} - \alpha^{2}} \right),} \\
 & {= - A_{1}\beta\frac{\gamma}{s_{1}}\left( {1 - \frac{s_{1}}{\gamma}\alpha} \right) + \frac{1}{2}A_{1}^{2}F^{2}\left( \alpha,\lambda,\kappa \right)\left( {\frac{\gamma}{s_{1}^{2}}^{2} - \alpha^{2}} \right),} \\
 & {\geq - \left( {\frac{\beta A_{1}\gamma}{s_{1}} - \frac{A_{1}^{2}F^{2}\left( \alpha,\lambda,\kappa \right)\gamma^{2}}{2s_{1}^{2}}} \right)\left( {1 - \frac{s_{1}}{\gamma}\alpha} \right),} \\
 & {\Psi\left( \alpha \right) \geq \Psi\left( \frac{\gamma}{s_{1}} \right) - \left( {\beta A_{1} - \frac{A_{1}^{2}F^{2}\left( \alpha,\lambda,\kappa \right)\gamma}{2s_{1}}} \right)\left( {\frac{\gamma}{s_{1}} - \alpha} \right).} \\
\end{aligned}$$Substituting the inequality [(15)](#fd15){ref-type="disp-formula"} into [(14)](#fd14){ref-type="disp-formula"}, we have $$\begin{aligned}
{\log\left( \lambda\left( t \right) \right) \geq} & {\mspace{1300mu}\log\left( \lambda\left( 0 \right) \right) + \Psi\left( \frac{\gamma}{s_{1}} \right)t} \\
 & {- \left( {\beta A_{1} - \frac{A_{1}^{2}F^{2}\left( \alpha,\lambda,\kappa \right)\gamma}{2s_{1}}} \right)\int_{0}^{t}\left( {\frac{\gamma}{s_{1}} - \alpha\left( u \right)} \right)du} \\
 & {+ A_{1}\int_{0}^{t}F\left( \alpha,\lambda,\kappa \right)\alpha\left( u \right)dW\left( u \right).} \\
\end{aligned}$$By our assumption $s_{1} = \mu$, Therefore $$\begin{aligned}
{\log\left( \lambda\left( t \right) \right) \geq} & {\mspace{1300mu}\log\left( \lambda\left( 0 \right) \right) + \Psi\left( \frac{\gamma}{\mu} \right)t} \\
 & {- \left( {\beta A_{1} - \frac{A_{1}^{2}F^{2}\left( \alpha,\lambda,\kappa \right)\gamma}{2\mu}} \right)\int_{0}^{t}\left( {\frac{\gamma}{\mu} - \alpha\left( u \right)} \right)du} \\
 & {+ A_{1}\int_{0}^{t}F\left( \alpha,\lambda,\kappa \right)\alpha\left( u \right)dW\left( u \right).} \\
\end{aligned}$$From Eq. [(1)](#fd1){ref-type="disp-formula"} of the system [(2)](#fd2){ref-type="disp-formula"}, $$\begin{aligned}
{d\alpha \geq} & {\left( {\gamma - \mu\alpha - \left( \frac{\frac{\beta\gamma}{\mu}\lambda}{1 + \frac{q\gamma c}{\mu b}} \right)} \right)dt} \\
 & {- \frac{F\left( \alpha,\lambda,\kappa \right)\alpha\lambda}{1 + q\kappa}dW\left( t \right),} \\
 \geq & \left( {\mu\left( {\frac{\gamma}{\mu} - \alpha} \right) - \left( \frac{\frac{\gamma}{\mu}\beta\lambda}{1 + \frac{qc\gamma}{\mu b}} \right)} \right) \\
 & {- \left( \frac{F\left( \alpha,\lambda,\kappa \right)\alpha\lambda}{1 + q\frac{\gamma c}{\mu b}} \right),} \\
{\mu\int_{0}^{t}\left( {\frac{\gamma}{\mu} - \alpha\left( u \right)} \right)du \leq} & {\alpha\left( t \right) - \alpha\left( 0 \right) + \frac{\beta}{\left( {\frac{\mu}{\gamma} + \frac{qc}{b}} \right)}\int_{0}^{t}\lambda\left( u \right)du} \\
 & {+ A_{1}\int_{0}^{t}F\left( \alpha,\lambda,\kappa \right)\alpha\left( u \right)\lambda\left( u \right)dW\left( t \right),} \\
\end{aligned}$$Substituting the above inequality in Eq. [(16)](#fd16){ref-type="disp-formula"}, we arrive at $$\begin{aligned}
{\log\left( \lambda\left( t \right) \right) \geq} & {\mspace{1300mu}\Psi\left( \frac{\gamma}{\mu} \right)t} \\
 & {- \frac{\beta}{\mu}\left( \frac{1}{\frac{\mu}{\gamma} + \frac{qc}{b}} \right)} \\
 & {\left( {\beta A_{1} - \frac{A_{1}^{2}F^{2}\left( \alpha,\lambda,\kappa \right)\gamma}{2\mu}} \right)\int_{0}^{t}\lambda\left( u \right)du} \\
 & {+ \Lambda\left( t \right),} \\
\end{aligned}$$where $$\begin{aligned}
{\Lambda\left( t \right)} & {= \log\left( \lambda\left( 0 \right) \right) - \frac{1}{\mu}\left( {\beta A_{1} - \frac{A_{1}^{2}F^{2}\left( \alpha,\gamma,\kappa \right)\gamma}{2\mu}} \right)\left\lbrack \alpha\left( t \right) - \alpha\left( 0 \right) \right.} \\
 & \left. \mspace{2600mu} + A_{1}\int_{0}^{t}F\left( \alpha,\lambda,\kappa \right)\alpha\left( u \right)\lambda\left( u \right)dW\left( u \right) \right\rbrack \\
 & {\mspace{2600mu} + A_{1}\int_{0}^{t}F\left( \alpha,\lambda,\kappa \right)\alpha\left( u \right)dW\left( u \right),} \\
\end{aligned}$$By Strong Law of large numbers for martingales, $$\lim\limits_{t\rightarrow\infty}\frac{\Lambda\left( t \right)}{t} = 0\quad a.s.$$Thus, $$\lim\limits_{t\rightarrow\infty}\inf\frac{1}{t}\int\limits_{0}^{t}\lambda\left( u \right)du \geq \frac{\Psi\left( \frac{\gamma}{\mu} \right)}{\left( \frac{\beta\gamma b}{\mu\left( \mu b + qc\gamma \right)} \right)\left( {\beta A_{1} - \frac{F^{2}\left( \alpha,\lambda,\kappa \right)\gamma^{2}A_{1}^{2}}{2\mu}} \right)}\quad a.s.$$ [(2)](#fd2){ref-type="disp-formula"} is proved.From the Eq. [(3)](#fd3){ref-type="disp-formula"} of system [(2)](#fd2){ref-type="disp-formula"}, $$d\kappa \geq \left( {c\left( \frac{\gamma}{s} \right) - b\kappa} \right)dt$$Upon integration on both sides and dividing by $t$, $$\frac{b}{t}\int_{0}^{t}\kappa\left( u \right)du \geq c\left( \frac{\gamma}{s} \right) - \left( \frac{\kappa\left( t \right) - \kappa\left( 0 \right)}{t} \right)$$As $\left. t\rightarrow\infty, \right.$ we have $$\lim\limits_{t\rightarrow\infty}\left( \frac{\kappa\left( t \right) - \kappa\left( 0 \right)}{t} \right) = 0.$$Finally, $$\lim\limits_{t\rightarrow\infty}\inf\int\limits_{0}^{t}\kappa\left( u \right)du \geq \frac{\gamma c}{\mu b}\quad a.s.$$which proves our assertion [(3)](#fd3){ref-type="disp-formula"} *.*This completes the proof of [Theorem 4](#thm4){ref-type="statement"}.  □

In most dynamical systems, our aim in the analysis of mathematical models is to determine the asymptotic behavior of its solutions. To be precise, in the language of dynamical systems, to determine the nature of global attractor. Biologically speaking, the nature of treatment that would evoke appropriate immune response in the host such that the severity of the infection is stabilized.

Remarks 3The Local Lipschitz condition of the function $F\left( \alpha,\lambda,\kappa \right)$ is sufficient because it is evident from [Theorem 1](#thm1){ref-type="statement"} that the solution to the system exists globally in the domain $\mathbb{D}$ for infinite time and the above theorem also speaks about the infection dynamics in the host system even for the permanent type under any initial value of $\alpha,\lambda,\kappa.$

The above [Theorem 4](#thm4){ref-type="statement"} ensures the survival of the members of the interacting population ensuring their existence despite infrequent large perturbations which is often experienced by biological systems in nature over a longer period of time whatever be the state of the system. Our aim is to control the infection at any stage even though it is permanent.

It is also important to analyze that the results achieved should represent a larger population irrespective of time which is next in row.

2.5. Time invariance-stationary distribution and positive recurrence {#sec2.5}
--------------------------------------------------------------------

Before moving to empirical analysis, let us discuss the stationary distribution and positive recurrence of the persistence of system [(2)](#fd2){ref-type="disp-formula"} whose implications are given above and are established by the following theorem.

Theorem 5*The solution* $\left( \alpha\left( t \right),\lambda\left( t \right),\kappa\left( t \right) \right)$ *of system* [(2)](#fd2){ref-type="disp-formula"} *with any positive initial value* $\left( \alpha\left( 0 \right),\lambda\left( 0 \right),\kappa\left( 0 \right) \right) \in \mathbb{D}$ *, where* $\left. F\left( \alpha,\lambda,\kappa \right) = f\left( \alpha - \alpha_{2} \right)/ \equiv 0 \right.$ *is positive recurrent and admits a unique ergodic stationary distribution in* $\mathbb{D}$ *if* $R_{0} > 1$ *and* $$\eta_{1} = \left( {\mu - \frac{4cq\beta\alpha_{2}\lambda_{2}}{bn^{2}}} \right)\left( \alpha - \alpha_{2} \right)^{2} + \frac{1}{2}\frac{F^{2}\left( \alpha,\lambda,\kappa \right)\left( \frac{\gamma}{\mu} \right)^{4}}{\left( 1 + q\kappa \right)^{2}}\left( {n\lambda_{2}\left( \frac{\mu}{\gamma} \right)^{2}} \right),$$ *is positive on* $H^{c}$ *for* $n = \alpha_{2}$ *and* $b = \frac{p\alpha_{2}}{c} + \frac{q\beta\alpha_{2}^{2}}{c\left( 1 + q\kappa_{2} \right)}$ *.*

ProofThe ideas in the proof has been rented from the Lemma in appendix by Zhu ([@b42]) in his paper that begins with defining a bounded open subset $H$ of $\mathbb{R}^{3}$ as $$H = \left\{ \left( \alpha,\lambda,\kappa \right) \in \mathbb{D} \middle| N < \alpha < \frac{\gamma}{\mu} - N, \right.\left. M < \lambda < \frac{\gamma}{\mu} - M,P < \kappa < \frac{\gamma}{\mu} - P \right\},$$ where $N,M$ and $P$ are positive constants to be chosen as $\left. \alpha_{2}/ \in \overline{H}, \right.$ and $\lambda_{2},\kappa_{2} \in H$ followed by the diffusion matrix associated with the system $$dX\left( t \right) = b\left( X \right)dt + \sum\limits_{r = 1}^{k}\sigma_{r}\left( X \right)dW_{r}\left( t \right),$$given by $$A\left( \alpha,\lambda,\kappa \right) = \begin{pmatrix}
{\alpha^{2}\lambda^{2}F^{2}\left( \alpha,\lambda,\kappa \right)} & {- \alpha^{2}\lambda^{2}F^{2}\left( \alpha,\lambda,\kappa \right)} & 0 \\
{- \alpha^{2}\lambda^{2}F^{2}\left( \alpha,\lambda,\kappa \right)} & {\alpha^{2}\lambda^{2}F^{2}\left( \alpha,\lambda,\kappa \right)} & 0 \\
0 & 0 & 0 \\
\end{pmatrix}.$$We know that $\overline{H} \subset \mathbb{R}_{+}^{3},$ $$\begin{aligned}
{a_{11}\left( \alpha,\lambda,\kappa \right)} & {= \alpha^{2}\lambda^{2}F^{2}\left( \alpha,\lambda,\kappa \right)} \\
 & {\geq \min\limits_{{(\alpha,\lambda,\kappa)} \in \overline{H}}\alpha^{2}\lambda^{2}F^{2}\left( \alpha,\lambda,\kappa \right)} \\
 & {\geq k_{1},} \\
\end{aligned}$$where $k_{1}$ is a positive constant. Thus, the condition $\left( i \right)$ in the Lemma is satisfied. It remains to prove $\left( ii \right)$ of Lemma for which we adapt the following steps.Define a non-negative function $$V_{2} = = \frac{1}{2}\left( \alpha - \alpha_{2} \right)^{2} + n\left( {\lambda - \lambda_{2} - \lambda_{2}\ln\frac{\lambda}{\lambda_{2}}} \right) + \frac{b}{2}\left( \kappa - \kappa_{2} \right)^{2},$$for $n = \alpha_{2}$ and $b = \frac{p\alpha_{2}}{c} + \frac{q\beta\alpha_{2}^{2}}{c\left( 1 + q\kappa_{2} \right)}$.Applying $\mathcal{L}$ on $V_{2}\left( \alpha,\lambda,\kappa \right),$ we have $$\mathcal{L}V_{2} \leq - \left( {\mu - \frac{4cq\beta\lambda_{2}}{b\alpha_{2}}} \right)\left( \alpha - \alpha_{2} \right)^{2} - \frac{b\alpha_{2}^{2}}{c}\left( \kappa - \kappa_{2} \right)^{2}\quad + \,\frac{1}{2}\frac{F^{2}\left( \alpha,\lambda,\kappa \right)\alpha^{2}\alpha_{2}\lambda_{2}}{\left( 1 + q\kappa \right)^{2}}.$$ Since $\alpha + \lambda \leq \frac{\gamma}{\mu}\quad\text{and}\quad\kappa \leq \frac{\gamma}{\mu}\frac{c}{b}$, we get, $$\mathcal{L}V_{2} \leq - \left( \left( \eta_{1}\left( \alpha,\lambda,\kappa \right) + \frac{b}{2}\left( \kappa - \kappa_{2} \right)^{2} \right) \right..$$Also, since $\eta_{1}\left( \alpha,\lambda,\kappa \right) > 0$ on $H^{c},$ we have $$\eta_{1}\left( \alpha,\lambda,\kappa \right) + \frac{b}{2}\left( \kappa - \kappa_{2} \right)^{2} \geq \inf\limits_{{(\alpha,\lambda,\kappa)} \in H^{c}}\frac{b}{2}\left( \kappa - \kappa_{2} \right)^{2} = \theta > 0.$$From this, we get $$\mathcal{L}V_{2}\left( \alpha,\lambda,\kappa \right) \geq - \theta\quad\text{for~all}\quad\left( \alpha,\lambda,\kappa \right) \in H^{c}.$$Hence, the assertion $\left( ii \right)$ of the Lemma is proved.  □

Thus, we have established the existence of a unique ergodic stationary distribution to our model.

Before moving on to the task of numerical simulations (i.e.), the empirical support which we spoke often in the previous sections, let us halt here for a moment to introspect ourselves why we need to simulate the mathematical model. The simple reason that comes first in our mind is that the construction is made under certain assumptions that differs from the real world problem to a little extent to make the models mathematically analyzable. So, it is necessary that our model lives up to our expectations i.e., copes up with the real world situation. Next, we have to ensure the robustness of the model under any situations not breaching the assumptions we made earlier during construction. All those questions get answered when we put the model into an artificial environment similar to the real world and simulate to show the results we achieved theoretically in the previous sections.

3. Empirical support via simulations {#sec3}
====================================

In this section, let us consider some examples to visualize our findings by simulating the stochastic system [(2)](#fd2){ref-type="disp-formula"} using an algorithm similar to Monte-Carlo simulation. In Monte-Carlo simulation, we generate a set of suitable multidimensional sample paths on $\left\lbrack 0,T \right\rbrack$. We generate a large finite set of paths, large enough so that, for example, any statistical information for the solution that we want to extract is sufficiently robust. For each sample path, we generate a sample path solution to the stochastic differential equation on $\left\lbrack 0,T \right\rbrack$. Consider an example as follows: $$d\alpha = \left( {\gamma - \mu\alpha - \frac{\beta\alpha\lambda}{1 + q\kappa}} \right)dt - \left( {\left( \frac{\mu}{\gamma} \right)^{4}\alpha\lambda\left( \alpha - \alpha_{2} \right)} \right)dW\left( t \right)$$$$d\lambda = \left( {\frac{\beta\alpha\lambda}{1 + q\kappa} - a\lambda - p\lambda\kappa} \right)dt + \left( {\left( \frac{\mu}{\gamma} \right)^{4}\alpha\lambda\left( \alpha - \alpha_{2} \right)} \right)dW\left( t \right)$$$$d\kappa = \left( c\lambda - b\kappa \right)dt$$ where $\alpha,\lambda,\kappa,\gamma,p,q,a,b\mspace{510mu}\text{and}\mspace{510mu} c$ are positive constants.

One can compare the above example with our stochastically perturbed model [(2)](#fd2){ref-type="disp-formula"}. Here, $\alpha_{2} = \frac{\left( a + p\kappa_{2} \right)\left( 1 + q\kappa_{2} \right)}{\beta} = \frac{c\gamma\left( 1 + q\kappa_{2} \right)}{c\mu + \left( b\beta + c\mu q \right)\kappa_{2}}$ with $R_{0} = \frac{\gamma\beta}{a\mu}$

All the simulations are carried out with step size 10^−2^. The expectations and variances are taken for about 10,000 trajectories with time scaled over days.

The following figures in the succeeding pages will give a crystal clear idea on the dynamical behavior of random effects in the viral infection model and their drastic influence in the course of infection and treatment. All the figures from 1--5 appear to be smooth because they are mean approximations of 10,000 sample paths simulated under random perturbation. It does not represent the smoothness of the system. However, the effect of environmental fluctuation of the system [(2)](#fd2){ref-type="disp-formula"} is presented through [Fig. 6](#fig6){ref-type="fig"}, [Fig. 7](#fig7){ref-type="fig"} which will give a clear picture of the importance of including randomness in the mathematical model.

[Table 2](#tbl2){ref-type="table"} represents parameter values for which the system [(2)](#fd2){ref-type="disp-formula"} evinces disease free dynamics around equilibrium solutions.

It is observed that with the above parameter values, the system [(2)](#fd2){ref-type="disp-formula"} explores the chances the desired population may be free from disease. Also, hereby we may arrive at the conclusion that the system under our analysis admits global stable solutions at both the equilibrium points with the following results depicted in the form of graphs.

The following parameter values in [Table 3](#tbl3){ref-type="table"} ratify permanent infection in the system [(2)](#fd2){ref-type="disp-formula"}.

Next, we simulated the example [(20)](#fd20){ref-type="disp-formula"} with different initial values $\left( \alpha_{0},\lambda_{0},\kappa_{0} \right) = \left( 100,15,45 \right)$ and that resulted in [Fig. 2](#fig2){ref-type="fig"}, [Fig. 3](#fig3){ref-type="fig"} again, respectively. We inferred that there is no change in the stability of disease free equilibrium and endemic equilibrium systems and is globally asymptotically stable on $\mathbb{D}$ irrespective of any initial value. i.e., biologically speaking whenever (at any stage of infection) we started our inspection in the host system, our model is compatible enough to analyze the stability in the host disease dynamics irrespective of the time which proves the [Theorem 5](#thm5){ref-type="statement"} which gives theoretical strength for the long term behavior analysis of our model.

Though the model showed disease-free equilibrium for small changes in $\beta$ with proportional increase in the treatment rate, it ends up in the case of endemic equilibrium that upon decrease in treatment rate i.e., if the same infection rate is simulated but for different values of $a = 0.8,\mspace{1300mu}\mu = 0.5,\mspace{1300mu} p = 0.04,\mspace{1300mu} q = 0.005,\mspace{1300mu} b = 0.31,\mspace{1300mu} c = 0.025$ resulted in [Fig. 5](#fig5){ref-type="fig"}.Fig. 4The above graph shows the simulated results inferred as we planned to observe the robustness of the model for notable small changes in infection and death rates related to both natural and infection related deaths with increase in the rate of immune response by $c = 0.95$. We present the inferred results as below: For the increase in rates of $\beta = 0.002$, the infection rate, $\mspace{1170mu} a = 0.9$ and $\mu = 0.8$ which are disease related and natural death rates, the system showed stability around disease-free equilibrium for the initial values $\left( \alpha_{0},\lambda_{0},\kappa_{0} \right) = \left( 100,15,45 \right)$ and $\gamma = 300,\mspace{1300mu} p = 0.4,\mspace{1300mu} q = 0.5,\mspace{1300mu} b = 0.31,\mspace{1300mu} c = 0.95$ with $R_{0} = 0.8333 < 1$ and $\left( \alpha_{1},\lambda_{1},\kappa_{1} \right) = \left( 375,0,0 \right)$.

Since, the [Fig. 1](#fig1){ref-type="fig"}, [Fig. 2](#fig2){ref-type="fig"}, [Fig. 3](#fig3){ref-type="fig"}, [Fig. 4](#fig4){ref-type="fig"}, [Fig. 5](#fig5){ref-type="fig"} above show the mean approximations of the sample paths under numerical simulations conditions, it will be more realistic if we could a comparative study in the analysis of the stability between Model [(1)](#fd1){ref-type="disp-formula"} and [(2)](#fd2){ref-type="disp-formula"} which was an idea followed in the paper ([@b18]).Fig. 5In the above graph, it is clear that the with the failure of appropriate treatment at the right time, the disease may exist in the host system, thus, increasing the possibility of higher death rates.

Similarly for the endemic equilibrium solutions the comparative study in the analysis of the stability between Model [(1)](#fd1){ref-type="disp-formula"} and [(2)](#fd2){ref-type="disp-formula"} gives the following [Fig. 7](#fig7){ref-type="fig"}.Fig. 6This graph presents a clear picture of the effects of random noise in the disease-free equilibrium solution of the system [(2)](#fd2){ref-type="disp-formula"} for the initial values $\left( \alpha_{0},\lambda_{0},\kappa_{0} \right) = \left( 100,15,45 \right)$ and $\gamma = 300,\mspace{1300mu}\beta = 0.002,\mspace{1300mu} p = 0.4,\mspace{1300mu} a = 0.9,\mspace{1300mu}\mu = 0.8,\mspace{1300mu} q = 0.5,\mspace{1300mu} b = 0.31,\mspace{1300mu} c = 0.95$ with $R_{0} = 0.8333 < 1$ and $\left( \alpha_{1},\lambda_{1},\kappa_{1} \right) = \left( 375,0,0 \right)$.

3.1. Observations and discussions {#sec3.1}
---------------------------------

Let us make a momentary stay here before moving to the applications. We thought some discussions would be more fruitful based on our observations in empirical simulation.

1.Based on the simulated results in [Fig. 2](#fig2){ref-type="fig"}, it is evident that the infected cells and the immune responses evoked are both stable and tend to zero under the conditions deduced in [Theorem 2](#thm2){ref-type="statement"} with the parameter values from [Table 2](#tbl2){ref-type="table"} with $R_{0} = 0.45 < 1$ (i.e.), both the infective population and the immune response tend to zero implying that the viral dynamics is free from infection which has been assured in the [Theorem 2](#thm2){ref-type="statement"} as the system [(2)](#fd2){ref-type="disp-formula"} will remain disease free as long as $R_{0} < 1.$2.However, [Fig. 3](#fig3){ref-type="fig"}, displays clearly, the dynamics of virus in the course of research towards permanence of infection in the system [(2)](#fd2){ref-type="disp-formula"} (i.e.), the behavior of the solution around endemic equilibrium with values from [Table 3](#tbl3){ref-type="table"} under the specified conditions of [Theorem 3](#thm3){ref-type="statement"} which imposes the conditions for the system [(2)](#fd2){ref-type="disp-formula"} to revolve around the chronic infection, it has to exhibit the behavior that leads to $R_{0} > 1.$3.An interesting fact is inspected when simulating the model [(2)](#fd2){ref-type="disp-formula"} with parameter values giving $R_{0} = 1$. Even though there have been different attitudinal behavior with the values of $R_{0} < 1$ or $> 1$, the system [(2)](#fd2){ref-type="disp-formula"} behaved in the similar way of revolving around disease free equilibrium solution when the value of $R_{0}$ is exactly 1.4.Upon paying due attention, the results further proved that the model under our study displayed invariance towards the initial conditions.(i.e.), the system showed no changes when they are simulated with different initial values, for they are the dependents on the values of $R_{0}$ only, thus supporting the results of [Theorem 1](#thm1){ref-type="statement"}.5.Since, the parameter values used in the simulations are not from literature, we further extended our study in the direction of individual behavior of the members of the system [(2)](#fd2){ref-type="disp-formula"} so that they guarantee validity as any other models in the similar Literature. Here comes the [Fig. 5](#fig5){ref-type="fig"} to extend its support in this regard showcasing that with the increase in infection rates and lack/failure of appropriate treatment at the right time, the host population may end up in the outbreak of epidemics or at cellular level, uncontrolled spread may lead to immediate death.6.The [Fig. 6](#fig6){ref-type="fig"}, [Fig. 7](#fig7){ref-type="fig"} shows the effects of random noise and the importance of introducing randomness in the model [(1)](#fd1){ref-type="disp-formula"}. It is clear that the disease-free and endemic equilibrium solutions of the model [(2)](#fd2){ref-type="disp-formula"} are not smooth and environmental fluctuations have great influence in the dynamical behavior of the disease.7.The major difference one can see while comparing the deterministic and stochastic models is that in deterministic system the parameters are assumed to be constant which is not true biologically in day to day life. So, to make our analysis more realistic there arises a need for better theory which is provided by including the environmental variations while modeling the real world scenario mathematically. It is the place where Stochastic Perturbation theory comes into the play and gives valuable informations even in the absence of any biological experiments which prove to be cost effective and time consuming.

Next, we present an application to our system [(2)](#fd2){ref-type="disp-formula"} with a HIV Infection Model.

4. Applications to HIV Model {#sec4}
============================

Even though, the above simulation results give clear picture of the robustness of the model [(2)](#fd2){ref-type="disp-formula"} which gives the results for generalized viral infection types, it would be more appropriate to discuss with infection disease models of special and global threat types thereby imparting knowledge about the advantages and disadvantages of adopting different approaches. So, next, we chose the universally spread viral infection viz., HIV with Non-linear incidence. This proposed model has already been analyzed for fractional order by Gang Huang et al. in [@b40]. Let us recall here that we have justified the advantages of using nonlinear incidence rate and look forward to some interesting results when we simulate with Stochastic Differential Equations by adding the environmental noise. The model under our consideration take up the following form with small perturbation in the infection rate $\frac{\beta xy}{1 + qx}$ as $\frac{\left( \beta + F\left( x,y,z \right) \right)xy}{1 + qx}\frac{dW}{dt}$ $$\frac{dx}{dt} = \overset{˙}{x} = \lambda - dx - \frac{\beta xy}{1 + qx} - \frac{F\left( x,y,z \right)xy}{1 + qx}dW$$$$\frac{dy}{dt} = \overset{˙}{y} = \frac{\beta xy}{1 + qx} - ay - pyz + \frac{F\left( x,y,z \right)xy}{1 + qx}dW$$$$\frac{dz}{dt} = \overset{˙}{z} = cyz - bz,$$ where $x$ denotes the uninfected population, $y$ represents the infected population and $z$, immune response evoked corresponding to the system [(21)](#fd21){ref-type="disp-formula"}. Here, the immune response gets stronger at the rate $cyz$ as assumed, is proportional to the number of infected cells and their concentration at present time. Also, we note that the immune response decays exponentially at a rate $bz$ proportional to its present time concentration whereas the parameter $q$ corresponds to the efficacy rate of Non-Lytic component with $d$ and $a$ referring the natural death rates of uninfected and infected population respectively. This model admits three equilibrium solutions namely disease-free equilibrium and endemic equilibrium in the presence of immune response and endemic equilibrium solution in the absence of immune response to the HIV infection in the host with the basic reproduction number i.e., the possibility of causing secondary infection by a single infected host in the entire infection period.

Before proceeding further we would like to give clear definitions of Immune presence equilibrium and Immune absence equilibrium states of the system.

DefinitionImmune Absence and Immune Presence EquilibriumThe immune absence equilibrium is the state of Latent infection stage in which the virus is entered into the host but is yet to produce infection so there is no role for the immunity to play.Immune presence equilibrium comes into the scene when the host shows signs of infection by the virus and the immune system starts its work to evade the infection from the host system.

The basic reproduction numbers are given by $R_{1} = \frac{\left( \beta - aq \right)}{c\left( d + q\lambda \right)}\left( cy_{1} - b \right) + 1$ or $R_{1} = R_{0} - \frac{b\left( \beta - aq \right)}{c\left( d + q\lambda \right)}$ and $R_{0} = \frac{\lambda\beta}{a\left( d + q\lambda \right)}$ respectively. Here $x_{1} = \frac{a}{\beta - aq};\qquad y_{1} = \frac{d + q\lambda}{\beta - aq}\left( R_{0} - 1 \right);z_{1} = 0$ indicates the endemic equilibrium point representing the immune absence equilibrium solutions whereas $$x_{2} = \frac{- \left( b\beta + cd - cq\lambda \right) + \sqrt{\left( b\beta + cd - cq\lambda \right)^{2} + 4c^{2}dq\lambda}}{2cdq};$$$$y_{2} = \frac{b}{c};$$$$z_{2} = \frac{c}{bp}\left( \lambda - dx_{2} \right) - \frac{a}{p}$$ represents the immune presence endemic equilibrium solutions.Fig. 7This graph presents a clear picture of the effects of random noise in the endemic equilibrium solution of the system [(2)](#fd2){ref-type="disp-formula"} for the initial values $\left( \alpha_{0},\lambda_{0},\kappa_{0} \right) = \left( 125,25,75 \right)$ and $\gamma = 500,\mspace{1300mu}\beta = 0.005,\mspace{1300mu} p = 0.04,\mspace{1300mu} a = 0.8,\mspace{1300mu}\mu = 0.5,\mspace{1300mu} q = 0.005,\mspace{1300mu} b = 0.31,\mspace{1300mu} c = 0.025$ with $R_{0} = 6.25 > 1$ and $\left( \alpha_{1},\lambda_{1},\kappa_{1} \right) = \left( 329.8183,221.3320,17.8494 \right)$.Fig. 8This graph represents the disease-free equilibrium solution for the initial values $x_{0} = 50,y_{0} = 5,z_{0} = 15$ with parameter values in [Table 4](#tbl4){ref-type="table"} when $R_{1} = 0.9753 < 1$. Also, not forget that the $R_{0} = 0.8547 < 1$.

We simulated the above system [(21)](#fd21){ref-type="disp-formula"} in the following form and reviewed the results $$dx = \left( {\lambda - dx - \frac{\beta xy}{1 + qz}} \right)dt - \left( {\left( \frac{d}{\lambda} \right)^{5}xy\left( x - x_{2} \right)} \right)dW\left( t \right)$$$$dy = \left( {\frac{\beta xy}{1 + qz} - ay - pyz} \right)dt + \left( {\left( \frac{d}{\lambda} \right)^{5}xy\left( x - x_{2} \right)} \right)dW\left( t \right)$$$$dz = \left( cyz - bz \right)dt$$ where $x,y,z,\lambda,p,q,a,b\mspace{510mu}\text{and}\mspace{510mu} c$ are positive constants. The simulation is examined using an algorithm similar to Monte-Carlo Simulations.

1.The disease free equilibrium is achieved at the point $\left( 33.333,0,0 \right)$ for the parameter values in [Table 4](#tbl4){ref-type="table"} as shown in the [Fig. 6](#fig6){ref-type="fig"}(A--F).Parameter values for infection free dynamics is presented in [Table 4](#tbl4){ref-type="table"}.2.The immune present endemic equilibrium solutions are obtained for the values of parameters in the system [(22)](#fd22){ref-type="disp-formula"} given by [Table 5](#tbl5){ref-type="table"} with initial values $x_{0} = 70,y_{0} = 15,z_{0} = 25$ in [Fig. 7](#fig7){ref-type="fig"}.Parameter values that express chronic infection are presented in [Table 5](#tbl5){ref-type="table"}.

One may get puzzled why simulations for endemic equilibrium solutions are being carried out for the immune present case only. This is because our model [(2)](#fd2){ref-type="disp-formula"} has been modeled in such a way that the infection rate is being approximated in proportion to the immune response evoked due to the infection of uninfected cells. The above simulated example gave illustrious support to our theorems in practical view. Next, we conclude our works in this paper with some discussions based on the results observed. In the mean time, a spark flashed to draw an comparative study between the results observed by Huang et al. in [@b40] when we surveyed through the simulation results. We found that even though both methods (Fractional Differential Equations (FDE's) and Stochastic Differential Equations (SDE's)) could discover conditions for stability at equilibrium solutions the method by SDE's seems to emphasis early detection of infection outbreak in the host than FDE's. This conclusion was drawn based on the simulation results in the paper by Huang et al.Fig. 9This graph represents the immune present endemic equilibrium solution at the point $\left( x_{2},y_{2},z_{2} \right) = \left( 8.8760,4.5000,7.3049 \right)$) when $R_{1} = 1.3851 > 1$. Also, we found $R_{0} = 5.5556 > 1$.Table 4Parameters and Values --- Disease free dynamics.ParameterValueParameterValue$\lambda$10$p$0.6$d$0.3$q$0.009$\beta$0.01$b$0.3$a$0.3$c$0.332Table 5Parameters and Values --- Permanent infection.ParameterValueParameterValue$\lambda$10$p$0.1$d$0.3$q$0.01$\beta$0.2$b$0.9$a$0.9$c$0.2

The parameter values are taken from the paper cited in [@b40] to draw a comparative analysis of the model under different kinds of simulation (see [Fig. 8](#fig8){ref-type="fig"}, [Fig. 9](#fig9){ref-type="fig"}). So, modeling the infectious diseases using SDE's will give better approximations and represents a closer scenario to nature in the concept of best fit model.

5. Conclusion {#sec5}
=============

In Mathematical Modeling, the kind of differential equations that appeared in the play are Ordinary Differential Equations (ODE's) and Partial Differential Equations (PDE's). However, Ordinary Differential Equations are the widely used models when modeling real-life situations as they require only shorter simulation time and can be plotted easily with the available data. Stochastic Differential Equations (SDE's) are derived from ODE's when the reaction rates between the components of system take up probabilistic values. Computationally, they are slight complex than ODE's and are difficult to parametrize comparing ODE's. Thus, they promise more closer approximation to reality than ODE models.

In this paper, we present a mathematical analysis on global dynamics of the viral infection model constructed by Bartholdy et al. in [@b4] and Wodarz et al. in [@b36] and include the immune responses (the efficacy of Non-Lytic and Lytic components) directly which is very difficult to obtain in the viral infection models. We studied the existence of strong unique solution of nonlinear SDE's and provided a rigorous proof. This task is non-trivial as we deal with non-linear SDE's. Further, our investigation revealed a biologically relevant domain $\mathbb{D}$ on which random dynamics of Susceptible, Virus Population and Immune Responses with non-globally Lipschitz-continuous coefficients takes place. In the presence of erratic unbounded martingale-type noises this fact is non-trivial. Also, stochastic asymptotic stability of disease free and endemic equilibria has been discussed with the help of invariance principle and Lyapunov's second method.

Generally, stochastic asymptotic stability of equilibria is connected to the basic reproduction number $R_{0}.$ There may some possibilities in the real stochastic viral dynamics, that the infection can extinct even if the basic reproduction number is $R_{0} > 1$ and can develop if $R_{0} < 1$ but not in all cases. There is no such effect observed in the proposed model. The only possibility what the authors show is that for $R_{0} < 1$ the infection does extinct as it is in the deterministic model. In the proposed viral infection model no such effects are observed at both theoretical and simulated experimental levels. Sufficient conditions for stochastic asymptotic stability can found in terms of parameters and functional dependence on the variable contact and recovery rates. A remarkable fact of the criteria is that a sufficient condition for stability can be found for general local Lipschitz continuous $F_{i}$'s. The applicability of mathematical approach is demonstrated by some graphical illustrations and the simulations show parametric dependence of asymptotic stability of related equilibria in view of expectations and variances. In this paper, equal importance has been given for both disease-free equilibrium and endemic equilibrium solutions as we look at the current research scenario. In recent years, we felt that many active researches are being carried on those cases in which the disease or infections that continue to exist in the system for instance, HIV infections, AIDS etc and those infections like conjunctivitis are receiving less attention which one cannot deny. So, we thought of carrying out simulations with criteria that would provide a clear idea of the entire dynamics of the disease which may explore the possibilities of extinction as well as survival of the host, in cases of endemicity. Based on our observations, we would also like to add a comment on the type of immune response to be effected in the host because reducing the replicative rate of the virus population by Non-Lytic effector mechanisms is always beneficial whereas increasing the death rate of infected cells can be both detrimental and beneficial, in short, we are prone to side effects on larger scale. We also observed when we simulated the system [(22)](#fd22){ref-type="disp-formula"} it seems much effective in comparison with simulation results carried out with Fractional Order as it gives stability conditions in stronger sense. This statement is validated with the simulation results gained in Huang et al. in [@b40] showed that the with the parameter values $\lambda = 23.3,\mspace{1300mu}\beta = 0.5,\mspace{1300mu} a = 0.02,\mspace{1300mu} p = 10,\mspace{1300mu} q = 0.79,\mspace{1300mu} d = 0.09,\mspace{1300mu} b = 0.15,\mspace{1300mu} c = 0.0031$ even with higher efficacy rates of the Lytic and Non-Lytic Immune responses the basic reproduction numbers for both immune absence equilibrium $R_{0} = 31.4916 > 1$ and immune presence equilibrium $R_{1} = 30.2250 > 1$. The graphs in the paper ([@b40]) with the above values evidently shows that the endemic equilibrium stabilizes only after 150 days for smaller order of fractions $\alpha = 0.56,\alpha = 0.65$. If we look at the empirical study carried out in our paper, it is evident even a smaller rate of efficacies of Lytic and Non-Lytic components, the stabilization is at a much faster rate as our parameter values are nearly closer to those values in [@b40]. Also, based on our observations we conclude that our model seems to be sensitive to infective rates even though any explicit sensitivity analysis has not been carried out in this paper. The future scope of this article lies in introducing the idea of multi group models with random perturbation in the papers ([@b11], [@b33], [@b39]) by Ji. et al., J. Yu et al. and J. Tan et al. respectively, which will form a new frame work in the literature to analyze the mathematical models with more precision and accuracy.

 {#app}

In this section, we would like to introduce some preliminaries such as notations, definitions and theorems that would help in investigating the global dynamics of the stochastic model [(2)](#fd2){ref-type="disp-formula"} theoretically. For detailed content refer ([@b2], [@b7], [@b12]).

 {#appA.1}

Consider the $d$-dimensional stochastic differential equation (SDE) of the form $$dX\left( t \right) = f\left( X\left( t \right),t \right)dt + g\left( X\left( t \right),t \right)dW\left( t \right)$$with an initial value $X\left( t_{0} \right) = x_{0},\quad t_{0} \leq t \leq T < \infty$ where $\left. f:\mathbb{R}^{d} \times \left\lbrack t_{0},T \right\rbrack\rightarrow\mathbb{R}^{d} \right.$ and $\left. g:\mathbb{R}^{d} \times \left\lbrack t_{0},T \right\rbrack\rightarrow\mathbb{R}^{d \times m} \right.$ are Borel measurable, $W = \left\{ W\left( t \right) \right\}_{t \geq t_{0}}$ is an $\mathbb{R}^{m}$-valued random variable.

The infinitesimal generator $\mathcal{L}$ associated with the SDE [(23)](#fd23){ref-type="disp-formula"} is given by $$\mathcal{L} = \frac{\partial}{\partial t} + \sum\limits_{i = 1}^{d}f_{i}\left( x,t \right)\frac{\partial}{\partial x_{i}} + \frac{1}{2}\sum\limits_{i,j = 1}^{m}\left( {g\left( x,t \right)g^{T}\left( x,t \right)} \right)_{ij}\frac{\partial^{2}}{\partial x_{i}\partial x_{j}}$$

Theorem*(* $\mathbb{D}$ *-invariance).* [@b12] *as appears in* [@b7] *.Let* $\mathbb{D}$ *and* $\mathbb{D}_{n}$ *be open sets in* $\mathbb{R}^{d}$ *with* $$\mathbb{D}_{n} \subseteq \mathbb{D}_{n + 1},{\overline{\mathbb{D}}}_{n} \subseteq \mathbb{D},\mathbb{D} = \bigcup\limits_{n}\mathbb{D}_{n}$$ *and suppose* $f$ *and* $g,$ *satisfy the existence and uniqueness conditions for solutions of* [(23)](#fd23){ref-type="disp-formula"} *, on each set* $\left( t,x \right):t > t_{0},x \in \mathbb{D}_{n}.$ *Suppose there is a non-negative continuous function* $V$ *on* $\mathbb{D} \times \left\lbrack t_{0},T \right\rbrack$ *with continuous partial derivatives and satisfying* $\mathcal{L}V \leq cV$ *for some positive constant* $c$ *and* $t > t_{0},x \in \mathbb{D}.$ *If also,* $$\left. \inf\limits_{t > t_{0},x \in \mathbb{D} \smallsetminus \mathbb{D}_{n}}V\left( x,t \right)\rightarrow\infty asn\rightarrow\infty \right.$$ *then, for any* $X_{0} = x_{0}$ *independent of* $W\left( t \right)$ *such that* $\mathbb{P}\left( X_{0} \in \mathbb{D} \right) = 1,$ *there is a unique Markovian, continuous time solution* $X\left( t \right)$ *of* [(23)](#fd23){ref-type="disp-formula"} *with* $X\left( 0 \right) = x_{0},$ *and* $X\left( t \right) \in \mathbb{D}$ *for all* $t > 0$ *(a.s.).*

 {#appA.2}

Consider the $d$-dimensional SDE $$dX\left( t \right) = f\left( X\left( t \right),t \right)dt + g\left( X\left( t \right),t \right)dW\left( t \right),\quad t > t_{0},\quad X\left( t_{0} \right) = x_{0}.$$ Assume that $f$ and $g$ satisfy, in addition to the existence and uniqueness assumptions, $f\left( x^{\ast},t \right) = 0$ and $g\left( x^{\ast},t \right) = 0,$ for equilibrium solution $x^{\ast},$ for $t \geq t_{0}.$ Furthermore, let us assume that $x_{0}$ be a non-random constant with probability $1.$

DefinitionStable in ProbabilityThe equilibrium solution $x^{\ast}$ of the SDE [(25)](#fd25){ref-type="disp-formula"} is stochastically stable (stable in probability) if for every $\epsilon > 0$ and $s \geq t_{0}$ $$\lim\limits_{x_{0}\rightarrow x^{\ast}}\mathbb{P}\left( {\left. \sup\limits_{s \leq t} \right\|\left. X_{s,x_{0}}\left( t \right) - x^{\ast} \right\| \geq \epsilon} \right) = 0$$where $X_{s,x_{0}}\left( t \right)$ denotes the solution of [(25)](#fd25){ref-type="disp-formula"}, satisfying $X\left( s \right) = x_{0},$ at time $t \geq s.$

DefinitionAsymptotically Stable in ProbabilityThe equilibrium solution $x^{\ast}$ of the SDE [(25)](#fd25){ref-type="disp-formula"},is said to be stochastically asymptotically stable if it is stochastically stable and $$\lim\limits_{x_{0}\rightarrow x^{\ast}}\mathbb{P}\left( {\lim\limits_{t\rightarrow\infty}X_{s,x_{0}}\left( t \right) = x^{\ast}} \right) = 1.$$

Theorem[@b2]*Assume that* $f$ *and* $g$ *satisfy the existence and uniqueness assumptions and they have continuous coefficients with respect to* $t.$*(i) Suppose that there exist a positive definite function* $$V \in C^{2,1}\left( U_{h} \times \left\lbrack t_{0},\infty \right) \right) = \left\{ f:\left( U_{h} \times \left\lbrack t_{0},\infty \right) \right)\rightarrow\mathbb{R}:f^{\prime}\text{is~continuous} \right\}$$ *where* $U_{h} = {\left\{ x \in \mathbb{R}^{d}: \right\|\left. x - x^{\ast} \right\|\left. < h \right\}},$ *for* $h > 0,$ *such that* $$for\quad all\quad t \geq t_{0},\qquad x \in U_{h}:\mathcal{L}V\left( x,t \right) \leq 0.$$ *Then, the equilibrium solution* $x^{\ast}$ *of* [(25)](#fd25){ref-type="disp-formula"} *is stochastically stable.(ii) If, in addition,* $V$ *is decrescent (there exists a positive definite function* $V_{1}$ *such that* $V\left( x,t \right) \leq V_{1}\left( x \right)$ *for all* $x \in U_{h}$ *) and* $\mathcal{L}V\left( x,t \right)$ *is negative definite, then the equilibrium solution* $x^{\ast}$ *is stochastically asymptotically stable.*

 {#appA.3}

DefinitionPersistence in MeanThe Stochastic Model [(2)](#fd2){ref-type="disp-formula"} is said to be persistent in mean ([@b6]), if $$\lim\limits_{t\rightarrow\infty}\inf\frac{1}{t}\int\limits_{0}^{t}\alpha\left( u \right)du > 0,\quad\lim\limits_{t\rightarrow\infty}\inf\frac{1}{t}\int\limits_{0}^{t}\lambda\left( u \right)du > 0,\lim\limits_{t\rightarrow\infty}\inf\frac{1}{t}\int\limits_{0}^{t}\kappa\left( u \right)du > 0,$$ where $\left( \alpha\left( t \right),\lambda\left( t \right),\kappa\left( t \right) \right)$ is any positive solution of the system [(2)](#fd2){ref-type="disp-formula"}.

Lemma[@b21]*Suppose* $A \in C\left( \mathbb{R}_{+} \times \Omega,\mathbb{R}_{+} \right)$ *and* $\Lambda \in C\left( \mathbb{R}_{+} \times \Omega,\mathbb{R} \right).$*If there exist positive constants* $v_{0}$ *and* $v$ *such that for all* $t \geq 0,$ $\log A\left( t \right) \geq v_{0}t - v\int_{0}^{t}A\left( u \right)du + \Lambda\left( t \right)$ *and* $\lim_{t\rightarrow\infty}\frac{\Lambda\left( t \right)}{t} = 0$ *a.s. then* $\lim_{t\rightarrow\infty}\inf\frac{1}{t}\int_{0}^{t}A\left( u \right)du \geq \frac{v_{0}}{v}$ *a.s.*

A.4 {#d1e24098}
---

Consider a $d$- dimensional stochastic differential equation $$dX\left( t \right) = b\left( X \right)dt + \sum\limits_{r = 1}^{k}\sigma_{r}\left( X \right)dW_{r}\left( t \right),$$and the diffusion matrix is defined as follows $$A\left( x \right) = \left( a_{ij}\left( x \right) \right),\qquad\qquad a_{ij}\left( x \right) = \sum\limits_{r = 1}^{k}\sigma_{r}^{i}\left( x \right)\sigma_{r}^{j}\left( x \right).$$

LemmaZhu ([@b42])*The system* [(29)](#fd29){ref-type="disp-formula"} *is positive recurrent if there is a bounded open subset* $H$ *of* $\mathbb{R}^{d}$ *with regular (i.e.), smooth boundary, and*(i)*there exist some* $i = 1,2,\ldots,d$ *and a positive constant k such that* $$a_{ii}\left( x \right) \geq k\qquad\text{for~any}\quad x \in H,$$(ii)*there exists a non negative function* $\left. V:H^{c}\rightarrow\mathbb{R} \right.$ *such that* $V$ *is twice continuously differentiable and that for some* $\theta > 0,$ $$\mathcal{L}V\left( x \right) \leq - \theta,\qquad\text{for~any~}\quad x \in H^{c}.$$*Moreover, the positive recurrence process* $X\left( t \right)$ *has a unique stationary distribution* $\mu\left( . \right)$ *with density* $\mathbb{R}^{d}$ *such that for any Borel set* $B \subset \mathbb{R}^{d}$ $$\lim\limits_{t\rightarrow\infty}\mathbb{P}\left( t,x,B \right) = \mu\left( B \right),$$ *and* $$\mathbb{P}\left\{ {\lim\limits_{T\rightarrow\infty}\frac{1}{T}\int_{0}^{T}f\left( X\left( t \right) \right)dt = \int_{\mathbb{R}^{d}}f\left( x \right)\mu\left( dx \right)} \right\} = 1$$ *for all* $x \in \mathbb{R}^{d}$ *and* $\left. f:\mathbb{R}^{d}\rightarrow\mathbb{R} \right.$ *be a function integrable with respect to the measure* $\mu$ *.*

Next, we include references that are helpful to bring out this study on viral infections.
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